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31ST BETHESDA CONFERENCE
Emergency Cardiac Care: Introduction
Gordon A. Ewy, MD, FACC, Conference Co-Chair,
Joseph P. Ornato, MD, FACC, FACEP, Conference Co-Chair
There are more than five million visits to Emergency
Departments in the U.S. each year for evaluation of chest
discomfort or other symptoms suggesting acute cardiac
ischemia. These evaluations generate over $10 billion in
hospital costs alone. In addition, over one million Ameri-
cans have an acute myocardial infarction each year, and
.250,000 people die of sudden, unexpected cardiac arrest.
Treatment of these conditions can be broadly termed
“Emergency Cardiac Care.” The American College of
Cardiology has recognized this specialized area for decades.
In fact, the 13th Bethesda Conference in 1981 was devoted
to this subject (1). At that time, the principal focus was on
the identification and management of patients with an acute
cardiac emergency. Consensus guidelines were developed
for “optimal emergency cardiac care before hospital admis-
sion, in the Emergency Department, and in the 6 h after
hospital admission.”
Since then, there have been major advances in the
prehospital and in-hospital treatment of patients who have
an acute coronary syndrome or who experience sudden,
unexpected cardiac arrest. Prehospital care has improved
markedly with the development of effective Emergency
Medical Services (EMS) systems. Out-of-hospital defibril-
lation capability, in its relative infancy in 1981, has become
the standard of care of first-responding fire engine compa-
nies and ambulances in most urban and suburban locales.
Now some cities, such as Rochester (Minnesota), Pittsburgh
and Cincinnati, even equip law enforcement officers with
automated external defibrillators. We now have security
officers in most Las Vegas casinos and airline flight atten-
dants aboard many U.S. commercial aircraft who are trained
and equipped to defibrillate cardiac arrest victims.
The 31st Bethesda Conference represents consensus
opinions and recommendations of experts from a variety of
disciplines on 1) the initial management of patients with
sudden, unexpected cardiac arrest; 2) the initial evaluation
and treatment of patients who present with symptoms
suggesting the presence of an acute coronary syndrome; and
3) the facilitation of emergency cardiac care research requir-
ing a waiver of informed consent. The principal focus of the
conference was not on the development of clinical practice
guidelines, but rather on a modified Delphi approach used
to develop consensus opinions and recommendations on
critical questions for which absolute or hard data are
incomplete. Conference deliberations occurred in each of
the three areas just noted. Specific discussions on the initial
evaluation and treatment of patients with symptoms sug-
gesting the presence of an acute coronary syndrome were
divided into prehospital and in-hospital components.
Since 1981, there have been significant advances in
cardiopulmonary resuscitation (CPR) and defibrillation.
Although there is now clear evidence showing that by-
stander CPR significantly increases neurologically intact
survival from cardiac arrest, several studies have documented
reluctance on the part of the general public to perform
mouth-to-mouth resuscitation on a stranger (2–4). A major
topic of discussion at the 31st Bethesda Conference was
whether the current national CPR guidelines for lay persons
should be simplified, by not including a recommendation
for bystanders to perform mouth-to-mouth resuscitation.
Surprisingly, there is an increasing body of scientific evi-
dence suggesting that it may not be essential to provide such
ventilation during the first few minutes of cardiac arrest due
to ventricular fibrillation (VF) (5–7). The present state of
knowledge supports consideration of an etiology-based
approach for CPR: 1) ABC CPR for asphyxial cardiac
arrests and 2) chest-compression-only CPR for initial treat-
ment of VF by the lay public. Perhaps the advancement that
will have the greatest impact has been the development of
the automatic external defibrillator. Specific recommenda-
tions are made (see later outline).
There have also been major advances in the recognition
and treatment of patients with an acute coronary syndrome.
Several of these advances were discussed in detail at the 31st
Bethesda Conference, and several new recommendations
were made regarding application of these new therapies in
the prehospital and Emergency Department setting. There
are detailed discussions on the complex issue of how to
evaluate patients with chest discomfort, as well as a review
of the diagnostic technologies and approaches to the initial
management of patients with a suspected acute coronary
syndrome.
Despite these advances, further progress has been hin-
dered by the difficulty of performing emergency care re-
search on impaired human subjects who are not able to give
informed consent. This is particularly problematic in the
area of cardiac arrest research, where all of the patients are
unconscious and where promising new drugs or devices
must be used early if they are to have any hope of success. In
most cases, there is insufficient time to contact the family
member to get consent. In 1996, Congress issued “Final
Rules” (21 CFR 50.24) allowing for a waiver of informed
Journal of the American College of Cardiology Vol. 35, No. 4, 2000
© 2000 by the American College of Cardiology ISSN 0735-1097/00/$20.00
Published by Elsevier Science Inc. PII S0735-1097(99)00656-7
consent under very limited circumstances. Unfortunately,
these rules have also created a new set of obstacles for
researchers. Specifically, they require a vaguely defined
community consultation and a public disclosure program.
At the 31st Bethesda Conference, there were extensive
discussions on this topic, and substantive new recommen-
dations have emerged.
Finally, perhaps the most significant element of this
exciting conference was the multidisciplinary representation
of its participants. In 1981, cardiologists dominated the
conference. In 1999, cardiologists still accounted for the
largest percentage of participants. However, for the first
time at a Bethesda Conference, there were a large number of
emergency physicians. In addition, the conference included
internists, family practitioners, prehospital care and/or fire
service personnel, representatives of government agencies
(including the National Heart, Lung, and Blood Institute of
the National Institutes of Health and the Food and Drug
Administration [FDA]), pediatricians, specialists in nuclear
cardiology and echocardiography, basic science researchers,
nurses, epidemiologists and educators. The recommenda-
tions derived from this exciting conference truly represent a
broad range of relevant perspectives.
The Steering Committee of the 31st Bethesda Confer-
ence recommends that the American College of Cardiology
formally endorse the following:
1. An educational program for the public and Institutional
Review Boards (IRBs) on the importance of and the
means to obtain a waiver of informed consent for research
on patients who have emergency cardiac conditions.
2. Physician education on how to cost-effectively risk strat-
ify the heterogeneous groups of patients who present
with signs and/or symptoms of an acute coronary syn-
drome.
3. Patients with myocardial infarction and hemodynamic
compromise, cardiogenic shock or other high risk criteria
should be triaged to medical facilities that have 24 h
staffed cardiac care services including emergency revas-
cularization (percutaneous coronary intervention and
coronary artery bypass graft surgery) and hemodynamic
support available, provided ambulance transport duration
is not excessive (.30 min). Triage should be performed
as soon as possible, preferably in the field or in the
nearest Emergency Department, depending on the med-
ical community.
4. There is now compelling evidence that automatic exter-
nal defibrillators (AEDs) can be safe and effective when
used by first responders, particularly if the time for
traditional EMS response is too long.
5. Continued research is needed in all areas of emergency
cardiac conditions, including each link in the chain of
survival.
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TASK FORCES
Task Force 1: Cardiac Arrest
Karl B. Kern, MD, FACC, Co-Chair, John A. Paraskos, MD, FACC, Co-Chair
Out-of-hospital or prehospital sudden cardiac arrest ac-
counts for an estimated 250,000 events each year (8). The
majority occur secondary to cardiac arrhythmias. A small
number, however, are due to asphyxia. The importance of
bystander CPR and early defibrillation in survival from
out-of-hospital cardiac arrest has been well documented.
Survival rates as high as 90% have been seen with early
defibrillation within the first minutes of cardiac arrest (9).
The likelihood of meaningful survival to hospital discharge
decreases by ;10% per minute thereafter. This has led to
the concept of the “chain of survival”: early access, early
CPR, early defibrillation and early advanced life support.
Each link is needed to improve cardiac arrest survival rates.
Geographic constraints, population density and EMS orga-
nizations are associated with meaningful survival rates from
out-of-hospital cardiac arrest from as low as 0% to as high
as 44% (10). Survival rates of #10% are the norm in many
areas.
Recent studies have shown the changing demographics of
out-of-hospital cardiac arrest (11–13). The incidence of
primary VF is declining, whereas the initial cardiac arrest
rhythm is increasingly bradyasystolic. This parallels an
increase in both the age-related and concurrent comorbid
heart diseases, especially congestive heart failure, in the
population of cardiac arrest victims.
BASIC LIFE SUPPORT CPR:
IMPROVING BYSTANDER CPR BY LAY RESCUERS
Standard, basic CPR (ABC CPR) is a coordinated integra-
tion of Airway management, rescue Breathing and chest
compression-induced Circulation. This technique has
proven to be life saving. However, CPR is performed
infrequently by bystanders, and when it is performed, the
quality is often disappointing. Insufficient force, inadequate
rate and interruption of chest compressions are particularly
significant problems. It is increasing clear that ABC CPR is
a complex psychomotor technique, and therefore it is
difficult to teach, learn, remember and perform under the
best set of circumstances. New educational approaches,
including video-based and home-learning systems, with
more opportunity for skill mastery, are under investigation
to address this dilemma (14). A significant effort to educate
family members of high risk individuals is also warranted.
The need to simplify basic life support (BLS) CPR is now
well recognized. It has been documented that lay persons
can neither remember nor perform ABC CPR as presently
taught (15–18). Accordingly, proving the efficacy of simpli-
fied techniques should be a high priority.
Routes to CPR simplification. Existing data support sev-
eral simplifications in BLS. Instruction to place the rescuer’s
hands “in the middle of the victim’s chest and push” have
resulted in hand positioning comparable to that of the
previous method of careful landmark identification and
measurement from the xiphoid process (19). European
studies have shown the futility of asking lay persons,
paramedics and even some physicians to judge the presence
or absence of a pulse in assessing for adequate circulation
(19,20). Elimination of the pulse check seems reasonable.
Cardiopulmonary resuscitation with chest compressions
only (i.e., no assisted ventilation) has been proposed as one
simplified technique that may encourage increased by-
stander CPR. Such a modification makes CPR easier to
learn and to master, and it alleviates the fears and concerns
associated with mouth-to-mouth contact. Animal studies
have established that prompt initiation of chest compres-
sions without assisted ventilation for 8 to 12 min can be as
effective as ABC CPR with respect to 24 h survival and
neurologic outcome after VF (21–25). Immediately after an
acute fibrillatory cardiac arrest, aortic oxygen and carbon
dioxide concentrations do not vary from the prearrest state,
because there is no blood flow and aortic oxygen consump-
tion is minimal. When effective chest compressions are
initiated, this oxygenated blood flows from the aorta to the
coronary circulation. Moreover, chest compression–induced
gas exchange and active gasping during CPR are well
documented (22,23,25). Importantly, these studies have
documented no outcome disadvantage with less than opti-
mal gas exchange from chest compressions alone, particu-
larly when associated with active gasping during CPR.
Two important clinical studies support the use of chest-
compression-only CPR for VF cardiac arrest. The Belgian
Cerebral Resuscitation Group (26) prospectively evaluated
3,053 prehospital cardiac arrest victims. Physicians on the
ambulance evaluated the quality and efficiency of bystander
CPR. Good-quality chest-compression-only CPR and
good-quality chest compressions plus mouth-to-mouth res-
cue breathing were comparably efficacious, and both were
more effective than no bystander CPR.
Hallstrom et al. compared chest compressions alone to
chest compressions plus assisted ventilation in the setting of
dispatcher-directed telephone-assisted bystander CPR
when the dispatchers determined that the bystander or caller
did not know CPR (A. Hallstrom, personal communica-
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tion, September 9, 1999). They randomly instructed these
nearly 500 bystanders to provide chest compressions alone
or chest compressions plus assisted ventilation. Survival to
hospital discharge was 10% after chest compressions plus
assisted ventilation and 14.5% after chest compressions
alone (p 5 0.09). Chest compressions alone was certainly
not worse than chest compressions plus assisted ventilation,
and the trend suggests it might be better.
Optimal BLS for asphyxial arrests is quite different.
Asphyxia results in progressive oxygen consumption and
carbon dioxide and lactate production before cardiac arrest.
Therefore, adequate myocardial oxygen delivery during CPR
for an asphyxial cardiac arrest requires re-establishment of
arterial oxygenation and improvement of pH through ade-
quate gas exchange in the lungs, as well as myocardial
perfusion. Chest compressions plus rescue breathing is the
treatment of choice for asphyxial arrest. However, labora-
tory and clinical experience suggests that patients with
asphyxial cardiac arrest can sometimes be resuscitated with
ventilation alone or compressions alone, despite a history of
pulselessness and unresponsiveness (i.e., it is better to do
“something” than “nothing”) (27).
The present state of knowledge supports consideration of
an etiology-based approach for CPR: 1) ABC CPR for
asphyxial cardiac arrests and 2) chest-compression-only
CPR for the initial treatment of VF by the lay public.
Patients with witnessed sudden collapse and adults with
unwitnessed arrests could be assumed to have VF, whereas
patients with a submersion event or a foreign body aspira-
tion or children with an unwitnessed arrest should be
assumed to have an asphyxial arrest.
Defibrillation first versus CPR first by the lay health care
provider. Ventricular fibrillation is uniformly fatal without
defibrillation. Immediate defibrillation is the treatment of
choice for a short episode of VF; the success of defibrillation
decreases dramatically with the passage of time, presumably
because of continued ischemia and progressive imbalance of
myocardial oxygen supply and demand. Conversion to a
perfusing rhythm with the first series of countershocks is a
major determinant of survival from VF (28), yet the rate of
such conversion with the first shock diminishes over time.
Should a brief period of CPR be provided before defibril-
lation attempts for prolonged VF? Experimental animal
studies have suggested that precountershock CPR for pro-
longed cardiac arrest can improve the defibrillation rate and
rate of initial successful resuscitation as compared with
immediate defibrillation attempts (29).
A recent prospective, observational investigation suggests
that precountershock CPR for 90 s improves survival (30).
After routine availability of AEDs, the overall survival rate
from prehospital VF did not improve in Seattle, despite a 3
to 4 min shortened time to defibrillatory shock in most
cases. Accordingly, Cobb et al. (30) compared an EMS
protocol to provide an initial period of ;90 s of CPR before
automated analysis of cardiac rhythm with defibrillation
first. Survival improved from 24% (155 of 639) to 30% (142
of 478) (p 5 0.04). As predicted, the survival benefit was
more impressive when the initial response interval was
.4 min (17% [56 of 321] vs. 27% [60 of 220]) (p 5 0.01).
MANAGEMENT OF VF/VT
Before Hospital Admission
Need for prospective, randomized trials. Prospective,
randomized trials need to be designed and funded to assess
the effectiveness of BLS/defibrillator capability in diverse
settings. Studies should follow the Utstein style and must
determine the effect of any changes on the eventual survival
of an integrated functioning individual; for this, particular
attention needs to be given to the reporting of neurologic
outcomes. The characteristics of the population being
served by the EMS system must be well defined. Intervals
from collapse to bystander CPR and collapse to defibrilla-
tion must be carefully assessed. Finally, all aspects of the
links in the “chain of survival” need to be carefully docu-
mented. All these data points, in the Utstein template, are
required if we are to compare the results of one study with
those of another. Armed with such data, the medical
profession will be in a better position to advise government
and private industry as to the most efficacious and cost-
effective manner of addressing the challenge of out-of-
hospital cardiac arrest.
Early defibrillation. USE OF AEDS BY FIREFIGHTERS AND
EMERGENCY MEDICAL TECHNICIANS. The development of
AEDs has been a major medical advance. Their develop-
ment not only holds the promise of early defibrillation, but
also decreases the level of training necessary for personnel to
defibrillate the out-of-hospital cardiac arrest victim. Since
1979, emergency medical technicians (EMTs) have been
trained to use either manual or automated defibrillators. At
about the same time, the use of AEDs by minimally trained
first responders (usually firefighters) became more frequent.
A review of pertinent studies evaluating firefighters and
others using AEDs is given in Table 1. In general, adding
firefighter or EMT defibrillator capability to existing ad-
vanced cardiac life support (ACLS) paramedic response led
to improved survival rates, although these data are mainly
derived from studies done in Seattle and King County,
Washington. It is unclear whether all areas will achieve
similar benefit.
USE OF AEDS BY LAW ENFORCEMENT PERSONNEL. Law
enforcement personnel provide cardiac arrest first-responder
care in an increasing number of communities. Recently, this
has often included training and equipping with AEDs. The
number of published studies evaluating law enforcement
defibrillation is limited. Table 1 reviews these studies. The
two published studies have shown variable results in time
response intervals and survival with law enforcement AED
use (28,36). Use of AEDs by law enforcement personnel
needs to be supported by the chain of survival if benefits are
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to be realized. In areas where time intervals to defibrillation
are not altered with law enforcement AED use, no benefit
should be expected.
DEFIBRILLATION ABOARD COMMERCIAL AIRCRAFT. The
number of deaths per year on commercial airlines due to
medical emergencies is not well defined, but estimates range
from 72 to 1,000 per year, with most of them being sudden
(40,45).
A number of factors unique to airline travel may exacer-
bate medical conditions, including stress of flying, exertion
in getting from one gate to another (especially when
carrying luggage), circadian disruption and reduced oxygen
in the cabin (equivalent to 6,000 to 8,000 feet). Further-
more, the aircraft cabin is poorly designed for recognition
and treatment of cardiac arrest. The most important limi-
tation in delivering treatment to cardiac arrest victims has
been the lack of access to defibrillation. Under the best of
circumstances, it takes 20 min to divert for an emergency
landing and another 10 to 15 min to reach a gate.
In 1990 and 1991, Virgin Atlantic and Qantas airlines,
respectively, began placing AEDs on their aircraft. There
were 27 deaths on Qantas aircraft, and only 16 (59%) of
these were “witnessed.” The initial rhythm was asystole or
pulseless idioventricular rhythm in 21 arrests (78%). Six
passengers were in VF, with five immediately converted and
two surviving long term (40). In addition, Qantas placed
AEDs near its terminal gates. There were 19 arrests in the
terminal, all witnessed, with 17 (89%) revealing VF as the
initial rhythm. Four of these patients (24%) survived long
term. In comparison with the experience aboard aircraft, the
higher percentage of those with VF as the initial rhythm
and the longer term survival reflect the fact that cardiac
arrest in the terminal is more likely to be recognized and
treated immediately.
In July 1997, American Airlines became the first U.S.
carrier to place AEDs aboard its aircraft, with flight atten-
dants trained in AED use. In the first nine months of the
program, the AED was used on cardiac arrest victims
aboard the aircraft 42 times and in the terminal on six
occasions. Seven individuals were in cardiac arrest: four were
in asystole or agonal rhythm and three had VF. One of the
three patients with VF has survived long term. It is
important to note that the device was placed during stable
rhythms in 41 individuals, but no inappropriate shock was
advised or delivered (41).
EXTERNAL DEFIBRILLATORS IN CASINOS. Security officers
in the gaming establishment can use AEDs to achieve
collapse-to-defibrillation intervals shorter than those feasi-
ble with traditional prehospital EMS systems. Security
officers trained by the Clark County Fire Department
(Nevada) yielded mean collapse-to-defibrillation intervals of
2.2 min in 10 cases of witnessed VF. Seven (70%) of the 10
victims survived to hospital discharge (43). The program has
subsequently been expanded, with the result that later
adopters of the program have demonstrated longer collapse-
to-defibrillation intervals and lower rates of survival after
witnessed VF. The following conclusions can be drawn
from this experience:
1. Rapid defibrillation can be achieved by appropriately
trained and motivated casino security officers, resulting
in high rates of survival.
2. Sufficient devices must be installed and located on site to
enable the arrival of an AED at the victim’s side in
#3 min.
3. The interval from call for assistance to arrival of an AED
must be tested prospectively from a representative set of
locations on each site.
4. Optimal initial and refresher training intervals for non-
traditional defibrillation providers remain to be estab-
lished.
5. Integration of rapid defibrillation programs with local
EMS services is necessary.
6. Physician oversight of casino defibrillation programs
needs to be addressed.
USE OF AEDS AT GATED COMMUNITIES, RESORTS AND
LARGE PUBLIC GATHERINGS. Public access to AEDs has
been implemented in a number of Palm Springs country
clubs under the auspices of a Coachella Valley-Wide Re-
suscitation Project (M. Weil, personal communication,
Table 1. Automatic External Defibrillators by Nonmedical First Responders
Provider Intervention Study Type Outcome References
Firefighter BLS/
defibrillation
Meta-
analysis
Improved survival to
hospital discharge
31–33
Police Defibrillation Historic
control
Improved survival as
compared with
baseline
28,34–39
Airline personnel AED Observational
study
Significant survival
rate (33%)
40–42
Casino personnel
(trained security guards)
AED Observational
study
Significant ROSC
rate (70%)
43,44
ROSC 5 return of spontaneous circulation.
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1999). Over the past four years, 10 golf resorts have
acquired AEDs as part of this community resuscitation
program. A total of 233 security and club personnel were
trained (23.3 persons per site); 29 defibrillators are currently
in use (2.9 defibrillators per site). A population of 16,640
individuals is covered (averaging 1,664 persons for each
site). The mean age of this population is 63.7 years (range
54 to 82). One defibrillator covers 574 individuals. There is
one defibrillator for an average of eight trained rescuers. The
cost of implementation was $11,030 per club, including
training, or ;$6.62 per member. Annual expenses were
;10% of the implementation cost ($1,100 per club and 66
cents per member). Club personnel arrive at the scene
within 3.5 min (range 1 to 5), and professional rescuers after
an additional interval of 6 min (range 4 to 8). The AEDs
have been used on six occasions. Defibrillation was required
and successfully resuscitated one victim before the arrival of
professional rescuers. The victim survived with hospital
discharge and no neurologic impairment. The remaining
five cases represented preparedness to defibrillate in settings
of acute dyspnea (n 5 4) and syncope (n 5 1).
LAY PUBLIC DEFIBRILLATION—BARRIERS AND SOLUTIONS.
Although the concept of lay public defibrillation is appeal-
ing, there are certain barriers to consider. Is it possible that
use of AEDs by lay rescuers may harm either the patient or
the operator? What is the likelihood that some collapse will
be misdiagnosed as VF? Previous work has shown that the
rhythm detection algorithms in the AED devices are excel-
lent for distinguishing VF and non-VF rhythms. In one
out-of-hospital cardiac arrest series, 103 of 106 “shockable”
rhythms were recognized and a shock was delivered (46).
The three cases of VF that were not shocked were all
in-patients with pacemakers, where the pacer spikes were
superimposed during VF. In contrast, no shock was advised
or delivered in all 950 cases of “nonshockable” rhythms,
including asystole (427 [45%] of the 950). How much harm
is done to a cardiac arrest victim who is shocked mistakenly?
These and a number of other questions also remain. Can VF
be caused by a mistaken shock? What level of defibrillation
should be used for children? If a lay person is harmed by
improper defibrillation, who is liable?
It is probable that the selected lay person who is highly
motivated and capable of operating a defibrillator will need
to undergo retraining. Laws need to be passed to indemnify
individual operators, training centers and their personnel
and locations where defibrillators are used. Such “good
Samaritan” laws are currently in place in some states, but not
all. Federal statutes may also be needed.
An additional cadre of questions arises around the actual
administration of lay public defibrillation programs. Who
will control the development and implementation of defi-
brillator programs for the lay public? Organizations with
appropriate physician expertise, such as the American Col-
lege of Cardiology (ACC) and American Heart Association
(AHA), could assume leadership.
USE OF AEDS BY NONTRADITIONAL PROVIDERS. The po-
tential efficacy of early defibrillation by nonmedical first
responders has been demonstrated by numerous studies.
There now exists compelling evidence that AEDs can be
safe and effective when used by first responders, including
police, firefighters and first-tier EMS providers. However,
although the results are largely favorable, they are not
uniformly so. The studies without favorable results high-
light the importance of the incremental time gained by
employing nontraditional providers of AEDs, as well as the
importance of all links in the “chain of survival,” to obtain
improved results with early CPR and early defibrillation.
One important yet unresolved issue is the proper interpo-
sition of CPR and incorporation of AEDs. Should defibril-
lation always take precedent or should a period of CPR
sometimes be done before defibrillation attempts? Experi-
mental laboratory studies, as well as one recently published
study in humans by Cobb et al. (30), indicated that for
individuals with cardiac arrest .5 min, a short duration (60
to 90 s) of chest compression is indicated before attempting
defibrillation.
The need for AEDs in large populations will depend on
the number of those at risk. In 1986, AEDs were made
available at the World’s Fair in Vancouver, British Colum-
bia. With 22 million visitors, there were only five cardiac
arrests, two of which were due to VF and were successfully
treated (47). The AEDs will be most effective in high risk
populations.
An example of a high risk population appears to be
elderly patients at casinos. It appears that AEDs can be
effectively used in these special circumstances by nontradi-
tional first responders. The use of AEDs by spouses and
family members of patients at high risk for cardiac arrest has
been tried, but has been largely superceded by the develop-
ment of effective implantable cardioverter-defibrillators.
Much work remains to be done before we can confidently
suggest the optimal method for 1) deployment of defibril-
lators; 2) training of nonmedical responders; and 3) meth-
ods of control and supervision of AEDs. The answers to
these problems will vary widely depending on geographic
constraints and population density, as well as population
risks. Rural, suburban and urban systems will undoubtedly
need to be designed very differently.
Use of AEDs in ambulatory care facilities. There are no
specific guidelines from accrediting organizations that pro-
vide recommendations for types of equipment and training
requirements in nonhospital-affiliated outpatient facilities.
Ambulatory care centers attached to hospitals fall under the
auspices of the Joint Commission for the Accreditation of
Health Care Organizations (JCAHCO) and use its new
guidelines for hospital-based resuscitation practices.
Little research has been done, to date, regarding emer-
gency cardiac care practices and preparedness in the outpa-
tient setting. A study of primary care provider offices
revealed that only 65% of offices had a physician or nurse
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trained in BLS, and only 39% had anyone trained in ACLS
(48). Defibrillation capability was only present in 6% of
offices. Thirty-five percent of offices had at least one medical
emergency in the two years before the study. Cardiopulmo-
nary resuscitation was required in two cases and one death
occurred. A cost analysis of providing AEDs and training of
two personnel in BLS/defibrillation over a 10-year period
only came to an additional 3 cents per outpatient visit.
Ambulatory care centers connected to hospitals typically
do not have adequate on-site resuscitation capabilities.
Appropriate equipment is lacking in many cases, and there
are significant personnel issues. Most physicians and nurses
in this setting are not trained in either BLS/defibrillation or
ACLS. Much of the physician staff is transient throughout
the day, which leaves the nursing staff as the only consistent
presence. It is imperative that the personnel most likely to
witness a cardiac arrest have the appropriate equipment and
training to respond promptly. The most likely way to
accomplish this is with the use of AEDs.
There is an emerging expectation from the public that
early defibrillation capabilities be widely available. Given
that the volume and acuity of patients seen in the ambula-
tory care setting are increasing, that staff has variable
presence and training, that early defibrillation is the inter-
vention most likely to improve survival in adult cardiac
arrest and that cost is relatively low, all outpatient facilities
should review their current preparedness for cardiac arrest
and consider implementation of an early defibrillation pro-
gram utilizing AEDs.
Hospital-Based Resuscitation
It has often been assumed that hospitals function as self-
contained EMS systems with respect to their management
of cardiac arrest, because there is an abundance of health
care providers in a defined environment. Unfortunately,
because of this incorrect assumption, the process of resus-
citation in the hospital has traditionally received less atten-
tion. The JCAHCO developed standards related to in-
hospital resuscitation that were released in December 1998,
effective January 1, 2000. The new standard TX.8 mandates
that effective resuscitation practices be available throughout
the hospital. The intent of TX.8 is that the mechanisms for
effective resuscitation include:
1. Appropriate policies, procedures, processes or protocols
governing the provision of resuscitation services.
2. Appropriate equipment placed strategically throughout
the hospital close to areas where patients are likely to
require resuscitation services.
3. Appropriate staff who are trained and competent to
recognize the need for and use of designated equipment
in resuscitation efforts.
4. Appropriate data collection related to the process and
outcomes of resuscitation.
5. Ongoing review of outcomes related to resuscitation, in
the aggregate, to identify opportunities for improvement
of resuscitation efforts.
It is likely that these new guideline requirements for
ongoing accreditation will stimulate hospitals to critically
evaluate the process by which resuscitation is performed, as
well as outcomes. The majority of U.S. hospitals are
deficient in one or more of these areas and will require
significant restructuring of their resuscitation efforts, includ-
ing early defibrillation capability with AEDs.
A comprehensive hospital-based resuscitation program
requires administrative and clinical support. A committee
should be formed consisting of members representing dif-
ferent areas of participation in the resuscitation effort. This
committee needs to have direct-line authority to someone
within the hospital administrative structure who cannot only
support improving the process of resuscitation from both
the financial and procedural standpoint, but who can also
follow through to make sure that appropriate policies are
enforced. The committee also needs to have a strong quality
improvement program to ensure that the process of resus-
citation is appropriate and to provide a basis for feedback to
personnel on the resuscitation team. The JCAHCO now
requires both of these processes.
The physical layout of the institution must be evaluated,
along with the patient population and staffing, to determine
the best way to provide timely defibrillation. Hospital
practice must shift from having CPR as the sole form of
BLS to including defibrillation as a BLS skill. Delayed
defibrillation occurs much less frequently in critical care
areas than on general floors, and this should be taken into
account when equipment choices are made. The AHA
recommends that hospitals should aim for a goal of deliv-
ering the first shock within 2 min of when the arrest was
determined in noncritical care areas (49).
There are adequate published data detailing that nurses
can be trained to use an AED appropriately and that they
can retain these skills over time. However, merely having
AEDs and nursing staff trained to use them is not enough.
From the clinical perspective, there appears to be significant
reluctance by many nurses to use the devices. One barrier
that must be overcome for a successful hospital-based AED
program is re-education and an “unlearning” of previously
learned behavior. The magnitude of this process should not
be underestimated.
Documentation of resuscitation efforts in the hospital is
typically inadequate and often inaccurate. Hospitals should
develop a documentation form specifically designed to
collect information on the process of resuscitation, as well as
any other information pertinent to their local quality im-
provement. There needs to be widespread education on
documentation of events during a cardiac arrest. This
education needs to include training on how to use the
specific documentation record, as well as the importance of
accurate information. Because the form used becomes a
medicolegal record, it is imperative that steps be taken to
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ensure completeness and accuracy. The same documenta-
tion form should be used throughout the hospital and
should include critical care areas as well.
The timing of events during in-hospital resuscitation is
one of the most important and least accurate parts of
documentation. There are typically several time intervals
used to document events during in-hospital resuscitation
efforts. Typically, someone from the hospital begins timing
events with their watch while waiting for the official code
team to arrive. There is also likely to be an initial time event
that gets documented by the hospital page operator as the
official start time. When the person responsible for docu-
mentation arrives on scene, a third time piece is often used
to document events.
There will be considerable inaccuracies, unless these time
pieces are synchronized. This has significant ramifications
from both a medicolegal as well as a quality improvement
perspective. The vast majority of hospitals have no method
of time synchronization, and therefore most data regarding
time to therapy may not be accurate.
Quality improvement and feedback are an integral part of
the resuscitation process in the hospital and are now
required by the JCAHCO. Many hospitals currently do not
support this process and must quickly change their ways to
be in compliance with the new standards. A good quality
improvement process includes complete and accurate doc-
umentation, retrieval of documentation forms from all areas
of the hospital (including intensive care units), personnel
trained to understand the process of ACLS who can
critically review the documentation record, a data base for
collection and trending of data and a method for providing
feedback to those performing resuscitation.
The National Registry of Cardiopulmonary Resuscitation
offers, for a small fee, an electronic data base specifically
designed for data collection of in-hospital cardiac arrest
events. It is based on the Utstein Guidelines for Documen-
tation and Reporting of Events for In-Hospital Resuscita-
tion, but is also applicable for pediatric populations. The
Registry provides precise definitions for all entries and thus
lessens the confusion when comparing data from different
institutions. Participating hospitals enter data from each
cardiorespiratory arrest into the electronic data base. This
information is sent confidentially to the coordinating center,
which will then prepare quarterly reports for each hospital.
Reports not only include information pertinent to each
hospital’s quality improvement program, but also provide
benchmark information comparing similar institutions.
This is the first large-scale data base of information and will
likely be able to fuel data-driven guidelines on hospital-
based resuscitation and ACLS. The process of improving
resuscitation in the hospital remains in its infancy.
Pharmacologic Adjuncts to Defibrillation
The prognosis is ominous for a sizable proportion of
patients with cardiac arrest in whom spontaneous circula-
tion is not restored by the first few defibrillation shocks and
in whom additional ACLS measures, such as endotracheal
intubation, epinephrine and antiarrhythmic medications,
are required.
Antiarrhythmic drugs. Antiarrhythmic drugs, including
lidocaine, bretylium, magnesium and procainamide, have
been classified as an “acceptable, probably helpful” treat-
ment for cardiac arrest secondary to ventricular tachyar-
rhythmias unresponsive to three or more shocks under
current ACLS guidelines. Although these drugs represent
current clinical practice in the U.S., there is limited evidence
supporting the benefit from use of these agents in treating
cardiac arrest victims. Use of antiarrhythmic agents has not
been universally embraced as an essential component of
treatment algorithms for shock-refractory cardiac arrest.
Evidence supporting any clinical benefit from early ad-
ministration of antiarrhythmic drugs in cardiac arrest is
scarce. In early animal trials, either resuscitation of VF was
not improved by the addition of procainamide or lidocaine,
or any benefit was offset by worsened short-term survival
attributed to the drugs’ adverse circulatory depressant ef-
fects. Ironically, lidocaine, procainamide, quinidine, phe-
nytoin and oral and higher doses of intravenous amiodarone
(10 mg/kg body weight) have all been observed to increase
the defibrillation threshold and, in theory, make it more
difficult to resuscitate hearts from VF (50–55).
In the only published case-controlled clinical trial in
which shock-refractory victims of out-of-hospital VF were
stratified according to those who did and those who did not
receive lidocaine, no significant differences were observed in
the return of an organized rhythm, admission to the hospital
or survival to hospital discharge between the treatment
groups (56). A retrospective evaluation of antiarrhythmic
drug use during a trial of active compression–decompression
CPR found that lidocaine and bretylium were indepen-
dently associated with a lower likelihood of survival to 1 h
after cardiac arrest (57). Another retrospective study com-
paring outcomes from a time when ambulances were or were
not staffed by personnel who were authorized to give
medications found that recipients of lidocaine were more
likely to have a return of spontaneous circulation and to be
admitted to the hospital, although no survival benefit was
demonstrated (58). In contrast, in a prospective, random-
ized trial comparing administration of lidocaine with stan-
dard doses of epinephrine in shock-refractory VF, not only
was there absence of benefit, but survival actually worsened
when such pharmacologic therapies served to delay defibril-
lation (59).
The current recommended use of magnesium in torsade
de pointes is supported only by case reports. Two recent
prospective, double-blind, randomized trials of cardiac ar-
rest in patients in the hospital and in the Emergency
Department found no benefit from routine treatment with
magnesium (60,61). Finally, none of the reported random-
ized trials comparing bretylium with placebo or with lido-
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caine in victims of cardiac arrest demonstrated any signifi-
cant differences in outcome between treatment groups (62).
In most studies to date, intravenous amiodarone has been
administered only after failure of other antiarrhythmic
medications to terminate malignant ventricular tachyar-
rhythmias. When compared with additional lidocaine and
epinephrine in dogs with shock-refractory VF pretreated
with prophylactic lidocaine, intravenous amiodarone signif-
icantly improved the success of subsequent defibrillation
(63). The Amiodarone in out-of-hospital Resuscitation of
REfractory Sustained ventricular Tachyarrhythmias trial
(ARREST), a recently published randomized, prospective,
double-blind, placebo-controlled trial, evaluated intrave-
nous amiodarone in out-of-hospital cardiac arrest due to VF
or pulseless ventricular tachycardia (64). In 504 randomized
patients, a significant improvement in admission to hospital
was observed in recipients of intravenous amiodarone as
compared with placebo (44% vs. 34%, p 5 0.03). The trial
was underpowered to detect differences in survival to hos-
pital discharge between the two treatment groups, which
tended to favor recipients of intravenous amiodarone. How-
ever, this is the only randomized, placebo-controlled clinical
trial ever to show a significant benefit from antiarrhythmic
drug therapy during CPR.
Conclusions. With the possible exception of intravenous
amiodarone, available evidence is inconclusive concerning
benefit of antiarrhythmic drugs in cardiac arrest. Most
studies addressing this question have been unpowered either
to demonstrate or necessarily exclude benefit from such
treatment or to have employed a positive but equally
unproven control (lidocaine) comparison. The dose and
manner in which to administer antiarrhythmic medications
during cardiac arrest and the optimal variables by which to
measure benefit from treatment (e.g., return of spontaneous
circulation, admission alive to the hospital, 24 h survival,
discharge from the hospital, neurologic function at hospital
discharge, one-year survival) also remain controversial.
Emerging Defibrillation Technologies
Electrical defibrillation of the heart was first accomplished
by using epicardial electrodes in the operating room. Sub-
sequently, transthoracic defibrillation by using first alternat-
ing and then direct current was introduced, with the latter
becoming the clinical standard. A damped sinusoidal
monophasic waveform has been the most commonly used
waveform in commercial external defibrillators. Experience
with implantable cardioverter-defibrillators indicated that a
biphasic waveform achieved lower defibrillation thresholds
in many patients. External defibrillators that use biphasic
waveforms have recently been introduced into clinical use.
Experimental studies in animals and humans, including
three clinical trials comparing biphasic with monophasic
waveforms in out-of-hospital cardiac arrest, have shown
that lower energy is required for successful defibrillation
with biphasic waveforms (Table 2).
Both monophasic and biphasic defibrillation may employ
a variety of waveforms (e.g., damped sinusoidal, monopha-
sic truncated exponential), which may not necessarily have
similar efficacy. Whether one waveform is more toxic than
another has not been well established. Multiple, high energy
transthoracic shocks can be associated with myocardial
necrosis and electrocardiographic (ECG) changes. The
latter appears to be less common with biphasic shocks of
equivalent efficacy.
Conclusions. Defibrillationcanbeaccomplishedwithtrans-
thoracic direct current shocks. The optimal waveform has
not yet been determined, but biphasic shocks usually have
lower energy requirements for conversion out of VF to
another rhythm. It remains to be determined whether
Table 2. Biphasic Versus Monophasic Waveforms for Out-of-Hospital Defibrillation
Waveform Study Type Outcome References
Monophasic-DS Randomized: 175 J vs. 320 J First shock defibrillation success rates
175 J 5 61%; 320 J 5 61%
Weaver et al. (65)
Biphasic-IC Case series First shock defibrillation rate 89% Poole et al. (66)
All shocks defibrillation rate 80%
Return to pulse in 56%
Biphasic vs. monophasic Case series, retrospective First shock defibrillation rates:
monophasic 75%; biphasic 83%
Gliner et al. (67)
All shocks defibrillation rate:
monophasic 74%; biphasic 91%
Biphasic vs. monophasic Randomized, clinical trial Defibrillation rate within three shocks:
monophasic 67%; biphasic 98%
Schneider et al. (68)
Survival to hospital discharge:
monophasic 32%; biphasic 28%
DS 5 damped sinusoidal; IC 5 impedance compensating.
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biphasic shocks will be associated with better clinical out-
comes in all situations, including pediatric cardiac arrest.
COST-EFFECTIVENESS OF PUBLIC
ACCESS DEFIBRILLATION (PAD) STRATEGIES
Economic Evaluation of
Treatments for Sudden Cardiac Arrest
Sudden cardiac arrest is debilitating and costly. Experts have
debated which outcomes should be considered when eval-
uating treatments for this illness. Additional insights may be
gained by considering the economics of treatments for
sudden cardiac arrest.
Health economic evaluation considers the tradeoff be-
tween the costs and effects of interventions. The direct costs
of treatment, the costs of subsequent medical care and the
costs of long-term care should be considered. If one treat-
ment is both more costly and more effective than another,
then the difference between the two interventions is ex-
pressed as an incremental cost-effectiveness ratio. Although
a variety of methods have been used to calculate incremental
cost-effectiveness ratios, an expert panel has proposed
guidelines that may be used to standardize these methods
(Table 3) (69).
Furthermore, a treatment can be considered cost-effective
in comparison with another if it is associated with an
incremental cost of less than twice the average annual
income per life year (i.e., approximately $50,000 per life year
in the U.S.) (70).
The following data have been expressed in 1999 U.S.
dollars.
Defibrillation. A decision analytic model combined effect
estimates from a meta-analysis with cost and quality of life
data to evaluate the incremental cost-effectiveness of de-
creasing the time to defibrillation (71). Decreasing the time
to treatment by addition of firefighters able to provide CPR
or defibrillation cost $63,700 per quality-adjusted life year.
Decreasing the time to treatment by addition of ambulance-
based providers cost $191,100 per quality-adjusted life year.
These estimates were limited by the quality of the under-
lying effectiveness data.
Another decision analytic model estimated the incremen-
tal cost-effectiveness of decreasing time to defibrillation by
implementing public access defibrillation (72). If this was
implemented by using lay responders, the program cost
$46,700 per quality-adjusted life year. If it was implemented
by using police, the program cost $29,000 per quality-
adjusted life year.
Also, decision analysis was recently used to assess the
incremental cost-effectiveness of decreasing time to defibril-
lation by training and equipping security guards in a gaming
establishment (73). Compared with usual care, early defi-
brillation cost $40,700 per life year, even after including all
future costs.
As yet, there has been no comprehensive evaluation of the
economics of defibrillation on passenger aircraft or in other
public settings (e.g., golf courses).
Advanced life support. Two studies have evaluated the
costs of advanced life support for sudden cardiac arrest. In
the decision analysis described earlier, implementation of
advanced life support cost $48,000 to $113,000 per quality-
adjusted life year (71). On the basis of cost data collected
from a retrospective case-series, advanced life support cost
$13,200 per life year (74). The former analysis considered
EMS costs and hospital costs, whereas the latter considered
EMS costs alone.
Conclusions. Economic analyses of treatments for sudden
cardiac arrest provide several insights into the economics of
emergency cardiovascular care. First, interventions that
shorten the time to defibrillation are likely to be cost-
effective if achieved by a low intensity intervention such as
police or lay responder defibrillation. Second, advanced life
support is an effective treatment for cardiac arrest, but it is
also expensive. There are conflicting data as to whether the
additional benefit of ACLS justifies the additional expense.
There are insufficient data to determine whether other
treatments for cardiac arrest are economically attractive.
Table 3. Guidelines for Economic Evaluations of Health Technologies
Comparison Intervention should be compared to existing practice.
Time horizon Long enough to capture all relevant future effects of intervention.
Design Acceptable to use either modeling or direct observation of costs and
effects.
Costs Including costs of health care services, patient time expended for
intervention, paid or unpaid caregiving, travel expenses and
nonhealth impacts of intervention.
Effects Morbidity and mortality should be accounted for by expressing effects
as quality-adjusted life years.
Quality of life Quality weights should be preference-based and measured on a scale
from 0 (equal to dead) to 1 (equal to optimal health)
Discounting Costs and effects should be discounted to present value.
Sensitivity analysis Values of variables should be varied to assess whether uncertainty
about key variables could have an impact on study conclusions.
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Finally, future economic evaluations of treatments of cardiac
arrest should adhere to current standards for cost-
effectiveness analysis.
CARDIAC ARREST: LEGAL AND LEGISLATIVE ISSUES
“Good Samaritan” laws were designed to protect and
indemnify the unskilled provider administering BLS. The
last decade, however, has shifted the burden of sophisticated
patient care to the outpatient arena and to health care
providers with lesser degrees of formal training. Several
previously defined “ACLS” tasks (i.e., defibrillation) are
now performed out of the hospital by nontraditional health
care providers. These events have exposed the inadequacy of
many existing Good Samaritan laws in dealing with current
resuscitation practice and the potential liability for out-of-
hospital health care providers and others.
In 1993, the AHA and other organizations endorsed
early defibrillation. Despite this extremely strong recom-
mendation, in 1996 and 1997, ,30% of first responders
nationwide were equipped with AEDs. One of the major
roadblocks to implementing the AHA recommendation was
that, in many states, the first responders (many times the
EMT) was not legally permitted to defibrillate. Subse-
quently, numerous studies demonstrated the overall safety
and efficacy of defibrillation (using AEDs) in the hands of
nontraditional health care providers (31,33,75–82) and
prompted several questions that warrant attention:
1. Who is a health care provider?
2. Who can defibrillate with an AED?
3. What is the legal risk for not only the user, but also the
trainer or the owner of a facility with an AED?
4. Who “regulates” or monitors such PAD programs?
5. What is the manufacturer’s liability if the device is used
“off-label”?
Who is a health care provider? The AHA sponsored
conferences on PAD and defined the traditional health care
provider as an individual with a duty to respond as part of
their professional job description (e.g., nurse, EMT). The
nontraditional health care responder, on the other hand, was
defined as someone who may encounter a medical emer-
gency but is not required to respond as part of their job (e.g.,
airline personnel, police, security guards). It was suggested
that all individuals trained in a physician-monitored AED
program be allowed to defibrillate.
Indemnification. Individuals, however, may be fearful of
litigation when using an AED or developing an AED
program. Along with effective AED training, it becomes
necessary to have mechanisms for immunity of not only the
user, but also the provider, trainer or person who owns the
AED (i.e., the AED acquirer). Both state and federal
legislation has introduced immunity for AED use when
implemented in programs under physician authorization.
Federal and state legislation. Over 42 states (as of Sep-
tember 10, 1999) have passed legislation that provides
immunity for the traditional and the nontraditional health
care provider when using an AED. Some of these laws
extend this protection to trainers, acquirers, owners and
other relevant individuals. These laws also support school
CPR training and authorization for AED use by EMTs. All
these statutes recommend that PAD programs remain
under physician authorization.
If state legislation has been so effective, what is the value
for additional federal legislation? The two should not be
thought of as mutually exclusive, but rather as mutually
supportive. State programs are limited in their scope, vary in
their provisions from state to state and do not have
jurisdictional control over federal facilities (e.g., military
bases, Veterans Affairs hospitals, the National Institutes of
Health, Indian reservations, national parks, courthouses).
Federal programs, however, are able to define minimal
national standards of excellence, and thus serve to standard-
ize the quality of care nationwide. This is not a new concept,
but is evident when one examines programs from the
National Highway Traffic Safety Administration. In addi-
tion, federal legislation is important for identifying future
jurisdictional control (i.e., issues pertaining to cardiac arrest)
by virtue of being applicable nationwide, and outcomes
impacted nationwide should reside at the national level.
ADVANCED CARDIAC LIFE SUPPORT
Use of Pressor Agents in the
Treatment of Refractory Cardiac Arrest
Patients in VF or ventricular tachycardia (VT) who fail
defibrillation and those in bradyasystolic states who fail BLS
need immediate therapy to reverse the metabolic effects of
ischemia on the myocardium if CPR is to be successful.
Basic life support, including ventilation and chest compres-
sion, is intended to generate an adequate coronary perfusion
pressure to provide improved flow of blood to the myocar-
dium. However, BLS efficacy is limited, and frequently the
clinician will need to proceed to therapy with drugs that
might increase myocardial blood flow.
The immediate goal of pressor therapy is to increase
vasomotor tone and increase coronary perfusion pressure to
improve blood flow to the heart and brain, improving the
chance of return of spontaneous circulation (ROSC) and
preventing continued brain injury.
Alpha-adrenergic receptor agonists, such as phenyleph-
rine, are powerful peripheral vasoconstrictors that redistrib-
ute blood to the brain and heart during CPR. Their effect is
principally on the arterial side of the circulation, and in
laboratory models they increase the rate of ROSC. Beta-
adrenergic agents, such as isoproterenol, cause significant
vasodilation and can worsen coronary perfusion pressure
during CPR. They can also increase myocardial oxygen
utilization, and thereby exacerbate the metabolic effects of
ischemia. When the beta receptor is blocked before admin-
840 Kern and Paraskos JACC Vol. 35, No. 4, 2000
Task Force 1: Cardiac Arrest March 15, 2000:825–80
istration of epinephrine, a mixed alpha- and beta-receptor
agonist, the resulting coronary perfusion pressure is in-
creased.
Stimulation of vasopressin’s V1 receptor results in vaso-
constriction that is mediated through a secondary messenger
system different from that used by adrenergic agonists. This
holds the promise of synergy when vasopressin is combined
with a catecholamine. Vasopressin may decrease oxygen
utilization by the myocardium, an effect that is theoretically
attractive.
Agent of Choice
Epinephrine has been the pressor of choice in the treatment
of refractory cardiac arrest (83,84). There are theoretic
reasons to consider the pure alpha agonists, such as phen-
ylephrine, because they raise intravascular pressure without
the potentially negative effect on myocardial oxygen utiliza-
tion. However, animal studies have failed to show a survival
advantage when phenylephrine was compared with epi-
nephrine (85). This potential advantage has not resulted in
adequate clinical investigation, and at this time, they are
rarely used.
Epinephrine, a catecholamine with mixed alpha- and
beta-agonist properties, is the agent of choice after failure of
defibrillation. Although laboratory and clinical investiga-
tions clearly indicate that it can raise perfusion pressure and
the rate of ROSC, it has not been unequivocally shown to
increase long-term survival. It may be that the paucity of
data supporting the use of epinephrine results from the drug
being the de facto standard of care for a disease in which
performance of placebo-controlled trials is problematic.
However, it is possible that the failure of epinephrine, in a
range of dosages, to improve long-term survival, may
represent a poorly defined toxicity. Clinical trials that
indicate toxicity are difficult to interpret because the epi-
nephrine dosage is a strong marker for duration of arrest,
which itself is the best predictor of poor outcome.
Recently, there has been considerable interest in the
potential utility of vasopressin in the treatment of refractory
cardiac arrest. In a series of laboratory and clinical investi-
gations, Lindner et al. (86–90) appear to have demonstrated
significantly better outcomes with vasopressin than with
epinephrine. There is also the possibility of using vasopres-
sin in combination with adrenergic agonists (91). Further
studies are needed.
Route and Dosage
In choosing a route of administration, the clinician must
balance timeliness against the potential of greater efficacy.
In most cases, epinephrine will be administered as a bolus of
1 mg by peripheral intravenous catheter, followed by a large
volume saline flush to assume rapid delivery of the epineph-
rine into the central circulation.
Although it may be possible to administer the drug more
quickly by endotracheal injection, bioavailability may not be
adequate. It is possible that increasing the endotracheal
dosage may overcome the decreased serum levels obtained
by this route. Intracardiac injection is not recommended
because intramural administration can reportedly cause
intractable VF.
There has been interest in dosages of epinephrine greater
than the traditional 1 mg. Laboratory investigations have
indicated that higher dosages may improve myocardial
blood flow and the rate of ROSC, but that survival may
actually be decreased (92). There have been a number of
randomized clinical trials of “high dose” epinephrine; in
none of these trials was there increased survival, although a
meta-analysis has shown improved rate of return of spon-
taneous circulation (93–95) (Stiell IG. Meta-analysis for
high dose epinephrine during CPR. Personal communica-
tion, 1999). Epinephrine duration of action is short-lived,
so that every 3-min dosing is recommended, although the
efficacy of subsequent doses is not well proven.
Potential Alternatives to
Standard Closed-Chest Compression
Standard chest compression produces ;25% to 35% of
normal cardiac output. There have been exciting develop-
ments in CPR adjuncts, for use by health care providers,
that appear to improve hemodynamic measurements during
resuscitation. These new developments include interposed
abdominal compression (IAC) CPR, active compression–
decompression CPR, vest CPR, phased chest and abdom-
inal compression– decompression CPR and open-chest
CPR.
These techniques have been difficult to study and evaluate
definitively for the following reasons: 1) they are often used
only late in resuscitation; 2) controversies persist regarding
study end points; 3) some of the devices used have not yet
received FDA approval; 4) the current health care environ-
ment favors conventional therapy and limits experimental
procedures; and 5) costs of prospective, randomized trials
can be prohibitive.
These alternative forms of resuscitation have solid labo-
ratory data, with some limited clinical data, supporting their
efficacy. They also demonstrate an acceptably low incidence
of adverse effects. Consideration of the use of these tech-
niques, when approved by the FDA, should come early in
the resuscitation effort. Successful use of these techniques
requires a commitment to adequate training and follow-up.
There is a continual need for randomized trials of such
alternatives to prove their efficacy as compared with stan-
dard CPR.
Interposed abdominal compression CPR. This type of
CPR requires the addition of mid-abdominal compressions
by an extra rescuer during the intervals between the chest
compressions of conventional CPR (96). The abdominal
compression point is located in the midline, halfway be-
tween the xiphoid process and the umbilicus. The recom-
mended force of abdominal compression is that sufficient to
generate ;100 mm Hg of external pressure on the abdom-
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inal aorta and vena cava and is equivalent to that required to
palpate the aortic pulse optimally when the heart is beating
normally. Interposed abdominal compression mathematic
models generate additional artificial circulation that is ap-
proximately equal to that created by chest compressions only
(97,98), potentially doubling blood flow during CPR. The
positive hemodynamic effects of IAC during CPR have
been confirmed in 16 of 17 animal studies using canine and
porcine models (99).
Three randomized clinical trials of IAC CPR for in-
hospital cardiac arrest have been done (100–102), two of
which have shown statistically significant improvement of
outcome measures (100,102). One randomized trial of
prehospital IAC CPR, combined when possible with stan-
dard CPR in the field, showed no difference in outcome
(103). These clinical studies are summarized in Table 4.
Pooled analysis of all available data for both prehospital and
in-hospital resuscitations shows statistically significant im-
provement in the return of spontaneous circulation with
IAC CPR. When only in-hospital studies are examined, the
effect of IAC becomes much greater. Pooled data from two
studies that examined long-term, neurologically intact sur-
vival after in-hospital resuscitations show a positive benefit
of IAC CPR as compared with standard CPR. Thus, strong
preclinical and clinical evidence supports the use of IAC
CPR for in-hospital resuscitations.
Practical implementation of IAC CPR is straightforward
and inexpensive. If the chest compressor counts “one—
AND—two—AND—three—AND . . . ,” the abdominal
rescuer applies pressure during “AND.” In the hospital, the
availability of an extra trained rescuer is rarely a problem.
The safety of IAC, as reviewed previously (104), has been
well documented in 426 humans, 151 dogs and 14 pigs.
Only one isolated case report of traumatic pancreatitis in a
child describes local trauma from abdominal compression
during CPR (105). These data compare favorably with the
well-known and frequent incidence of rib fracture and
pulmonary contusion from chest compression during CPR.
Increased emesis and aspiration from IAC have not been
reported, and there is evidence that if positive abdominal
pressure is applied during ventilations from the beginning of
an arrest, the rate of gastric inflation before endotracheal
intubation is reduced (106). Review of the available data,
therefore, suggests that there is much to be gained and little
to be lost from application of IAC CPR during in-hospital
resuscitations. Because the most favorable clinical results
have been obtained when IAC CPR is applied from the
beginning of resuscitation, early application of the technique
is to be encouraged. Use of IAC CPR as a last-ditch effort
after prolonged, failed ACLS is not recommended.
Active compression– decompression CPR device. Active
compression–decompression CPR is a method of CPR
utilizing a hand-held suction device to actively compress
and then decompress the chest during cardiac arrest. Al-
though chest wall compression achieves the same hemody-
namic effect as closed-chest manual CPR, active decom-
pression with the device decreases intrathoracic pressures,
leading to enhanced minute ventilation and venous blood
return to the thorax. Arterial systolic blood pressure, dia-
stolic blood pressure, coronary perfusion and vital organ
perfusion have been shown to be improved in nearly all
animal models of VF when ACD CPR is compared with
standard CPR (107–110). This increase in overall CPR
efficacy led to the development of both a new device (Ambu
CardioPump) and the performance of a number of clinical
in-hospital and out-of-hospital studies evaluating the po-
tential benefits of this approach.
Results from the clinical trials have been mixed. Al-
though some studies demonstrated no difference between
standard CPR and ACD CPR, other clinical trials point to
a significant improvement in resuscitation rates and 1 h
survival, especially in patients with witnessed cardiac arrests.
The most positive results come from Paris, where data
demonstrate that one-year survival is doubled with the use
of the CardioPump (5%) as compared with standard CPR
(,2.0%) (111). In contrast, other large studies have failed to
demonstrate any significant outcome improvement with
Table 4. Results of Clinical Studies of Interposed Abdominal Compression Cardiopulmonary Resuscitation (CPR)
Outcome Measure Studies IAC CPR Standard CPR p Value
Return of spontaneous circulation in or
out of the hospital
Mateer (103) 40/145 (28%) 45/146 (31%) 0.54
Ward (101) 6/16 (38%) 3/17 (18%) 0.19
Sack (100) 29/48 (60%) 14/55 (25%) 0.00014
Sack (102) 33/67 (49%) 21/76 (28%) 0.0067
All four studies 108/276 (39%) 83/294 (28%)
Return of spontaneous circulation after
in-hospital resuscitation
Ward (101) 6/16 (38%) 3/17 (18%) 0.19
Sack (102) 29/48 (60%) 14/55 (25%) 0.00014
Sack (104) 33/67 (49%) 21/76 (28%) 0.0067
All three studies 68/131 (52%) 38/148 (26%)
Survival to discharge, neurologically intact,
after in-hospital resuscitation
Ward (101) 1/16 (6%) 0/17 (0%) 0.3017
Sack (102) 8/48 (17%) 3/55 (5%) 0.0700
Both studies 9/64 (14%) 3/72 (4%)
IAC 5 interposed abdominal compression.
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ACD (112–115). No study has shown a worse outcome
when using ACD CPR as compared with standard CPR.
Although ACD CPR has been adopted by the EMS in
some countries, preliminary research has shown that the
benefits of ACD CPR can be improved by the use of an
inspiratory threshold valve (ITV) (116). This valve blocks
inspiratory gas exchange during the decompression phase of
CPR, thereby augmenting blood return to the chest and
overall efficiency of CPR. In patients in prolonged cardiac
arrest, use of the combination of ACD CPR plus the ITV
resulted in a higher and more rapid rise in end-tidal carbon
dioxide and significantly higher systolic and diastolic pres-
sures as compared with ACD CPR alone.
Vest CPR. With vest CPR, a bladder-containing vest
(analogous to a large blood pressure cuff) is placed circum-
ferentially around the patient’s chest (117). The bladder is
inflated and deflated by an automated pneumatic system to
cyclically compress the chest. Adherent defibrillation pads
can be placed on the chest before applying the vest to allow
for defibrillation without the need to remove the vest or
interrupt CPR.
Vest CPR was developed as a means of circumferentially
compressing the chest with the intention of reducing the
thoracic volume and increasing intrathoracic pressure (by
Boyle’s law) to an extent greater than that which could be
achieved with standard manual CPR (118–127). This
circumferential compression allows for a large amount of
force to be applied without the trauma inherent in applying
force to a single point, as with standard chest compression.
Laboratory data showed substantial improvement in hemo-
dynamic data and survival.
With the latest improved vest CPR system, hemody-
namic measurements in humans were improved significantly
over those of standard external chest compression (117).
Peak aortic pressure was nearly doubled (up to an average of
138 mm Hg), and coronary perfusion pressure increased by
50%. In addition, 4 of the 29 patients had return of
spontaneous circulation during vest CPR, despite their late
(50 6 22 min) resuscitation. In a second phase of the study,
patients were randomized to either vest CPR or standard
external chest compression after initial resuscitation efforts
had failed (11 6 4 min). There was a trend toward
improved initial resuscitation in the vest CPR group, but
the trial was too small to show a statistically significant
benefit. These data formed the basis for a large-scale,
randomized trial of vest CPR immediately after cardiac
arrest, which was performed on 81 patients in Europe and
showed a trend toward improved survival with vest CPR
(128).
Vest CPR requires a sophisticated device for its admin-
istration. The technique will obviously be limited to loca-
tions where the device would be readily available, although
a portable device may be possible. Application of the vest
itself is not difficult and can be performed successfully by
nurses given only a few minutes of instruction on its use. It
is likely that if vest CPR proves successful in improving
survival from cardiac arrest, it will remain predominately in
the hands of health care professionals. Currently, the vest
CPR system is too heavy and consumes too much energy to
be easily portable, as would be needed for treating out-of-
hospital cardiac arrest victims. The final utility of vest CPR
will be determined by the outcomes of larger clinical trials
and by whether the device can be miniaturized sufficiently
for routine clinical use.
Phased chest and abdominal compression– decompression
CPR. This technique incorporates chest compression–
decompression and ACD. A manually operated Lifestick
Resuscitator (Datascope, Fairfield, New Jersey) is employed.
The chest and abdomen are reciprocally compressed and
decompressed in a see-saw fashion.
Experimental studies demonstrated impressive hemody-
namic efficacy. The coronary perfusion pressure generated
by the Lifestick Resuscitator was threefold greater than that
generated by conventional precordial compression after
7 min of untreated VF. This was associated with improved
initial resuscitability and 72 h survival (129). Experimental
studies also indicated that the Lifestick Resuscitator mark-
edly improves efficiency and achieves greater myocardial
blood flow, cerebral blood flow (130) and minute ventilation
(131), with significantly lower compression force. Hemody-
namic efficacy was also demonstrated in a human case series
(132).
Open-chest CPR. Open-chest CPR, once the only treat-
ment option for victims of sudden cardiac arrest, quickly fell
out of favor with the advent of closed-chest resuscitation
techniques. Recognition of the generally poor hemodynamic
support generated with closed-chest CPR has spurred a
resurgence of interest in invasive forms of CPR.
Previous experimental work in both animals and humans
has shown improved CPR-generated hemodynamic data
and blood flow with direct cardiac massage. The fundamen-
tal unresolved issue is whether the improved hemodynamic
data will translate into an improved resuscitation outcome.
A number of laboratory experiments have shown an im-
proved outcome with the use of open-chest cardiac massage.
An important aspect in employing any invasive CPR
method is the time of application within the course of
cardiac arrest and the preceding resuscitation efforts. Al-
though open-chest massage may be superior to all forms of
closed-chest efforts, because of the inherent morbidity of the
associated emergent thoracotomy, it seems most reasonable
to try an initial period of closed-chest compressions fol-
lowed, as soon as possible, by external defibrillation at-
tempts. If successful, the morbidity of the emergent entry
into the chest is avoided. Experimental studies of cardiac
arrest with open-chest CPR have documented improved
coronary perfusion pressures, regardless of when it was
begun, but outcome was only improved when invasive CPR
was begun within 15 min of the onset of cardiac arrest
(133). These findings indicate that invasive techniques such
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as open-chest massage must be applied early, before exten-
sive myocardial injury occurs.
Limited human trials have confirmed the importance of
this “window of efficacy” for the successful use of invasive
CPR after unsuccessful standard closed-chest compressions.
Geehr et al. (134) reported a small series of 49 patients with
out-of-hospital cardiac arrest who were randomized to
standard closed-chest CPR versus initial closed-chest CPR
followed by emergent thoracotomy and open-chest massage
on arrival to the hospital. In this study, no survival benefit
was seen with the addition of open-chest massage. Scrutiny
of the times elapsed before the institution of invasive CPR
shows that none of the subjects received open-chest cardiac
massage within the first 20 to 25 min of their cardiac arrest.
Two recent nonrandomized human studies of open-chest
resuscitation confirm the superiority of open-chest direct
cardiac massage for hemodynamic support during cardiac
arrest and highlight the importance of total cardiac arrest
time on successful outcome with invasive CPR (135,136).
Alternative invasive techniques for resuscitation have
been developed, many of which have been carefully studied
in the past. With either direct mechanical ventricular
assistance or emergency cardiopulmonary bypass, the prin-
cipal issue remains the time to successful application in the
arrested patient. Generally, the more sophisticated the
device, the more difficult it is to use in a timely fashion
during cardiac arrest. One simplified concept that has
evolved recently is “minimally invasive direct cardiac mas-
sage.” Using only a limited 2-cm thoracotomy, a wand-like
device is inserted to directly compress the heart. The hope
is that by avoiding the necessary thoracotomy of typical
open-chest massage, the morbidity will be less and the
technique more acceptable. Studies of efficacy are currently
under way.
EVALUATION AND CARE AFTER RESUSCITATION
Most patients who are initially resuscitated die within 72 h
from persistent postresuscitation cerebral or myocardial
dysfunction. Efforts to understand and successfully treat this
postresuscitation syndrome are under way.
THE BRAIN DURING AND AFTER CARDIAC ARREST
Support of the brain during the postischemic period is
essential to survival after cardiac arrest. Most treatments
commonly administered after global brain ischemia have not
been formally tested in prospective, randomized clinical
trials. Generally accepted postresuscitation therapeutic goals
for brain preservation include the following.
Cerebral reperfusion. Maintenance of normal to high
cerebral perfusion (based on the individual patient’s baseline
blood pressure before arrest) is a mainstay of treatment.
Normally, cerebral blood flow is autoregulated so that blood
flow is independent of perfusion pressure over a wide range
of blood pressures (between ;50 and 150 mm Hg, mean
arterial pressure). During and after ischemia, autoregulation
is compromised, if not lost. Perfusion of ischemic tissue
then becomes passively dependent on arterial pressure. As a
result, the occurrence of postischemic hypotension compro-
mises cerebral blood flow and may result in significant
additional brain damage. Therefore, after restoration of
spontaneous circulation, arterial pressure should be rapidly
normalized using intravascular volume administration and
vasopressors, as needed (137), but may come at the risk of
increasing postresuscitation myocardial dysfunction by in-
creasing both preload and afterload.
Ventilation. Although the cerebral circulation may lose its
ability to adjust to blood pressure changes after ischemia,
responsiveness to arterial carbon dioxide and oxygen levels is
usually maintained and may lead to increased intracranial
pressure in the presence of hypercapnia or hypoxemia.
Hyperventilation may be effective in correcting postischemic
tissue acidosis and is important for excretion of the carbon
dioxide load generated from bicarbonate administration,
which may be given during CPR. Although the usefulness
of hyperventilation after global brain ischemia has never
been demonstrated, slight hyperventilation is usually recom-
mended after cardiac arrest to guarantee that hypercarbia
and the associated increase in intracranial pressure are
prevented.
Oxygenation. Adequate tissue oxygenation is necessary to
preserve cellular function and to allow postischemic repar-
ative processes to occur. The maintenance of moderate
hyperoxia (partial pressure of oxygen [PO2] .100 mm Hg)
seems judicious to prevent transient pulmonary problems
from causing a significant deterioration of oxygenation in
already compromised tissues. Adequate partial pressure of
oxygen in the arterial blood (PaO2) levels should be main-
tained using the lowest inspired oxygen fraction (FIO2)
possible with carefully titrated minimal levels of positive
end-expiratory pressure. Because hypoxia and hypercapnia
must be avoided, controlled ventilation, with muscle relax-
ation and sedation, if needed, has been recommended for at
least several hours after resuscitation.
Correction of acidosis. After brain ischemia, the decline of
pH correlates with the extent of cellular necrosis (138,139).
Cell damage is further accentuated by hypercapnia and
hyperglycemia. Treatment of severe acidosis is generally
believed to be clinically beneficial. Because the capacity of
respiratory compensation for a metabolic acid load is lim-
ited, administration of a buffer base is tempting, but
controversial. Unless effectively removed, increased carbon
dioxide production from bicarbonate neutralization can lead
to intracellular acidosis. Currently, the correction of intra-
cellular acidosis remains a clinical challenge.
Immobilization and sedation. The comatose brain can
and does respond to external stimuli, such as physical
examination and airway suctioning, with increases in cere-
bral metabolism. This elevation of regional brain metabo-
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lism requires increased regional cerebral blood flow at a time
when the oxygen demand-to-perfusion ratios are, at best,
precariously balanced. Protection from afferent stimuli with
administration of titrated doses of anesthetic drugs and
muscle relaxants may prevent the supply–demand imbal-
ance and improve the chances of neuronal recovery. All
activity that increases intracranial pressure, such as straining
or coughing, should be suppressed, and tracheal suction
should be performed with care.
Anticonvulsant therapy. Seizure activity can increase the
cerebral metabolic rate by 300% to 400%. This extreme
increase in metabolic demand may tip the tissue oxygen
supply–demand balance unfavorably, resulting in additional
tissue damage. Although the prophylactic use of anticon-
vulsant drugs (e.g., before a seizure occurs) is controversial,
it is generally agreed that the occurrence of a postischemic
seizure should be treated quickly and effectively. Commonly
used drugs include barbiturates, benzodiazepines and phe-
nytoin.
Glucose. Postischemic hyperglycemia has detrimental ef-
fects on cerebral blood flow, metabolism, edema formation
and neurologic outcome (140–142). Thus, after global brain
ischemia, hyperglycemia should be avoided and, if present,
treated aggressively. The administration of glucose should
be avoided, except in cases of verified hypoglycemia.
Corticosteroids. Although steroids are commonly admin-
istered to patients with intracranial pathology of any etiol-
ogy, available clinical studies of steroid use after cardiac
arrest suggest no benefit of this therapy (143,144).
Temperature control. The cerebral metabolic rate in-
creases ;8% per degree Centigrade of body temperature
elevation. Because the regional cerebral metabolic rate
determines regional blood flow requirements, elevation of
temperature above normal creates the possibility for a
significant imbalance between oxygen supply and demand.
Thus, temperature elevation should be treated aggressively
in the postischemic period, perhaps aiming at a slightly
subnormal body temperature.
Hypothermia, in contrast, suppresses cerebral metabolic
activity effectively and has been reported to have a protective
effect in global and focal ischemia (145–149). It has been
shown experimentally that temperature changes of only 2 to
3°C may limit the extent of ischemic brain injury. Hypo-
thermia, although not yet proven to be of clinical benefit, is
probably the most promising brain resuscitation therapy
currently on the horizon.
Conclusions. In the quest to improve survival after cardiac
arrest, concerns have been raised about the possibility of
increasing success in the resuscitation of patients while
creating increased numbers of survivors with severe residual
neurologic disabilities. However, available outcome data
from recent large-scale clinical trials allay these fears
(150,151). With very few exceptions, long-term survivors
demonstrated recovery of good neurologic function and
were able to lead independent lives.
Current rates of survival and recovery of intact neurologic
function after cardiac arrest are low. However, there is
reason for optimism. Not only are neurons more resistant to
ischemia than had been believed previously, but important
secondary mechanisms of tissue injury have also been
identified. These include generation of oxygen free radicals,
increased free intracellular calcium and excessive production
of excitatory amino acids and other neurotransmitters. Because
these secondary processes occur during postischemic reperfu-
sion, they allow opportunity for clinical intervention. Poten-
tially beneficial agents are now being developed and tested.
Unfortunately, none has yet been proven clinically effective.
MYOCARDIAL DYSFUNCTION AFTER RESUSCITATION
Postresuscitation myocardial dysfunction has been recog-
nized by resuscitation researchers for decades. Clinical
resuscitation trials have substantiated the importance of
postresuscitation myocardial dysfunction and its sometimes
fatal outcome. Myocardial postresuscitation dysfunction
may manifest itself as fatal recurrent ventricular arrhythmias
or persistent low cardiac output and shock. There is labo-
ratory evidence suggesting that the severity of postresusci-
tation myocardial dysfunction is related to the duration of
cardiac arrest, the residual effects of potent vasoconstrictors
used during resuscitation efforts and the use of high energy
defibrillation.
Experimental evidence of myocardial dysfunction after
successful resuscitation has come from a number of inde-
pendent investigators over the last decade. Decreases in
myocardial contractile function and left ventricular compli-
ance after resuscitation after 4 min of VF has been docu-
mented in both isolated, perfused rat hearts (152) and in
domestic pigs (153,154). Global left ventricular systolic and
diastolic dysfunction has been demonstrated in experimental
models after 10 to 15 min of untreated VF and subsequent
resuscitation. This global dysfunction has been shown to be
classic “stunning,” with profound mechanical compromise
in the presence of normal levels of myocardial blood flow
with spontaneous recovery if death does not occur (153).
Treatment and support of myocardial dysfunction after
resuscitation is just beginning to be explored. Because left
ventricular “stunning” is so reminiscent of what occurs with
recently transplanted hearts, similar treatments should be
effective. Dobutamine, which is often used to stabilize
patients who have had a heart transplant, has been studied
in animal models of prolonged cardiac arrest and induced
postresuscitation myocardial dysfunction. Left ventricular sys-
tolic and diastolic dysfunction improves with dobutamine
treatment (155). No survival benefit has yet been established.
Searching for a mechanism of this postresuscitation
phenomenon has suggested a role of the potassium adeno-
sine triphosphate channel. Experimental laboratory studies
have found less myocardial dysfunction after resuscitation
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and increased postresuscitation 48 h survival in animals
given a potassium adenosine triphosphate channel activator
(cromakalin) (156).
Conclusions. Postresuscitation myocardial dysfunction is a
common problem following prolonged cardiac arrest. It
appears to be a “stunning” phenomenon and is transient.
However, there is substantial morbidity and even mortality
associated with this period. An effective approach to treat-
ment of this postresuscitation left ventricular systolic and
diastolic dysfunction, once found, has the potential of
improving long-term survival from cardiac arrest.
Task Force 2: Acute Coronary
Syndromes: Section 2A—Prehospital Issues
Adolph M. Hutter, Jr., MD, MACC, Co-Chair, W. Douglas Weaver, MD, FACC, Co-Chair
Coronary heart disease (CHD) is the most common cause
of mortality for American men and women, accounting for
481,287 deaths in 1995 (8). Annually, an estimated
1,100,000 Americans experience a new or recurrent acute
myocardial infarction (AMI) due to CHD, and one-third of
them will die from that event (8). Although difficult to
quantify, it is estimated that annually 250,000 individuals
will die within 1 h of the onset of symptoms and before they
reach the hospital owing to cardiac arrest. Out-of-hospital
deaths account for more than one-half of all CHD mortal-
ity, and many of these victims have no history of CHD
(157). Coronary heart disease is prevalent, with ;14 million
Americans having a history of myocardial infarction or
angina pectoris, or both, with African American men and
women bearing a disproportionate burden (158).
Over the past 40 years, there has been a dramatic decline
in age-adjusted CHD mortality, which began in the mid-
1960s and continues today. From 1965 to 1994, the average
age-adjusted CHD decline was 2.8% per year (158). The
decline has lessened since 1990 (1.5%). Similarly, although
less dramatic, CHD incidence (new cases) and case fatality
have fallen, resulting in a rising prevalence of CHD (159–
162). These trends have led to a significant increase in the
expected life span of Americans (158). Less recognized is
the observation that absolute mortality has fallen only
slightly, as people still succumb to CHD, although now at
older ages.
The postulated reasons for this age-adjusted decline in
incidence, case fatality and CHD mortality are many
(157,163,164). However, it is clear that traditional risk
factor–based prevention and advances in medical therapy
for AMI and follow-up care have played an important and
increasing role in the decline. The advent of the coronary
care unit with intensive monitoring and treatment of com-
plications, along with reperfusion therapies such as throm-
bolysis, percutaneous transluminal coronary angioplasty
(PTCA) and coronary artery bypass graft surgery (CABG),
has contributed (157,165–167).
Among the more important goals in early care of CHD is
making these effective treatments available to patients in a
timely fashion (168). This is obvious for the victim of
cardiac arrest, but is also critical in reperfusion and other
therapies, where outcomes are improved when treatment is
delivered early.
PATIENT DELAYS
Several sources of delay inhibit the early application of
beneficial therapies. Widespread availability of these treat-
ments and recognition of the importance of timely applica-
tion have led to greater scrutiny of sources of delay and
programs to reduce delay.
The delay from the onset of symptoms of AMI to
definitive therapy (usually reperfusion) is commonly divided
into three periods (174). The first is from symptom onset to
the patient’s action to seek treatment, such as going to the
hospital or calling the emergency medical service (EMS).
This is the longest component of delay and constitutes from
60% to 70% of the total time.
The first step in this process is teaching patients and their
families the basic information they need to live successfully
with heart disease and to respond to unexpected symptoms.
A summary of educational goals is presented in Table 1
(169–171). Three categories of information are important:
1) practical information; 2) medications; and 3) risk factors.
Practical, concrete information is desired by patients more
so than detailed descriptions of the mechanism of ischemia
(172). This information includes how to avoid a heart
attack, what types of symptoms are worrisome and exactly
what to do when it is experienced (e.g., stop what you are
doing, rest and take up to three nitroglycerin tablets).
Many patients with heart discomfort report that their
symptoms were different from the sudden and dramatic
event they had expected (175). Longer delays in seeking
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treatment have been reported when the expected symptoms
did not match the experience (176). This discordance led to
a tendency to attribute symptoms to some other source or
condition (Finnegan et al., 1998). Women, in general, do
not view themselves at risk for a heart attack (Finnegan et
al., 1998). Misconceptions such as these need to be sus-
pected and clarified.
The second period is from deciding to seek attention to
arrival at the hospital. This is transport time whether by
ambulance, automobile or other means and is routinely 3%
to 8% of the total delay.
Finally, the time from arrival at hospital to definitive
therapy is the third period. Hospital assessment and treat-
ment decision comprises 25% to 33% of the total delay.
The delay period of patient symptom recognition and
decision making is long and has undergone considerable
study in recent years (177–180). A number of characteristics
are associated with longer delay, including older age, female
gender, African American race, low socioeconomic group
and no insurance. Surprisingly, an important characteristic
associated with prolonged delays is a history of CHD or
AMI. This counterintuitive observation is unexplained.
Environmental factors associated with increased delay in-
clude symptom presentation at home, having a spouse at
home, being with family members and attempting to
contact a physician. Factors associated with decreased delay
include symptom severity, typical symptoms and the belief
that CHD is preventable. Even when a decision is made to
seek medical help, most patients do not dial 911 for EMS
transport.
These associations may operate through a variety of
individual knowledge, beliefs, attributions and practical
barriers to taking action. A patient must recognize the
presence of abnormal symptoms, attribute them to a con-
dition requiring medical attention, decide to seek care,
arrange transportation and travel to the hospital. Barriers to
this process may arise from inadequate knowledge of heart
attack symptoms, maladaptive coping strategies, misattribu-
tion of the symptoms to noncardiac causes, denial, fear or
other characteristics (180,181). Patient denial is a particular
issue in those with known CHD. Any attempts to reduce
patient delay must confront these many factors.
There are considerable published data on the period for
prehospital delay. A review of data from 12 U.S. and
European studies published from 1969 to 1987 found that
median prehospital delay times ranged from 2.5 to 7 h, with
many patients waiting 12 to 24 h or more, with hospital
arrival at a time when reperfusion therapy was of unproven
benefit. Cooper et al. (182) describe a 6 h median delay time
for African Americans in 1983 to 1984. More recently,
however, the median delay time of 2.7 h for patients with
acute infarction with ST segment elevation in the U.S. was
unchanged over a two-year period (183). The Rapid Early
Action for Coronary Treatment (REACT) study found a
median delay time of 2.2 h at baseline in 20 cities (180).
PATIENT EDUCATION EFFORTS
Prodromal symptoms frequently are present in the days or
even weeks prior to the onset of AMI. Educational pro-
grams targeting recognition of such symptoms and early
action to seek help seem appropriate at this time. Because of
substantial patient delays to presentation, attempts have
been made to reduce this time. These methods have focused
on mass-media strategies supplemented by smaller media
and direct patient education. Ho et al. (184) utilized a
two-month mass-media campaign using television, radio
and newspaper in the Seattle metropolitan area. The median
delay time decreased from 2.6 to 2.3 h, which was not
statistically significant. Herlitz et al. (185) describe a one-
year campaign of mass and specialized media in Sweden
using newspaper, printed materials and radio. Patients
admitted to the coronary care unit had a statistically
significant decline in median delay, from 3.0 to 2.6 h. Those
with confirmed AMI had an even greater decrease of 0.7 h.
Gaspoz et al. (186), in a one-year mass-media and local
media campaign with television, radio, newspapers and
printed brochures in Switzerland, also demonstrated a
median delay time decrease from 3 to 2.7 h.
Table 1. Summary of Education/Instruction Goals by Physicians
What Should Be Taught? Supplemental Materials How Should Teaching Occur?
Practical, concrete
information (e.g., specific
symptoms to look for)
What to do when
experiencing chest
discomfort and how to
avoid it
Minimize information on
pathophysiology of chest
discomfort
Medication profile
Risk factor modification goals
Miniature electrocardiographic
copies
Wallet medication cards
Carefully selected brochures
Fifth-grade reading level (173)
Videotaped materials for
functionally illiterate
Computer health risk appraisals
Timing is important (no more
than 15 min)
Avoid confrontation in
preference for empathy (174)
Avoid fear or paternalism
Combination of approaches
(written and verbal) will help
achieve goal
Solicit and respond to questions
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Although none of these community studies was ideal in
design, much was learned. It appears that a mass-media
campaign, which is sustained, intense and supported by
other forms of communication, can reduce delay time.
The REACT trial attempted to improve on these design
differences with a randomized study of 20 cities with a
population of ;100,000 each in a sustained campaign of
over one year (180). It improved community awareness of
the problem and the proper action to be taken. The median
delay time (2.2 h) declined over the intervention; however,
similar changes were observed in the “control” communities.
Therefore, the differences were not statistically significant.
However, there were statistically significant delay time
declines in patients who called the 911/EMS system (20%),
favoring the intervention communities. Encouragement by
physicians to educate their patients with known CHD and
those at high risk about reducing delay had little effect. The
REACT trial provides evidence that community campaigns
to alert citizens and patients of appropriate action for AMI
can have an effect. However, a secular trend in delay time
suggests the need for new strategies if we are to further
reduce this delay. The cost-effectiveness of such programs is
unknown.
EMERGENCY MEDICAL SERVICES
AND ASSESSMENT OF CHEST DISCOMFORT
Current Emergency Medical Services
Access. Time is a critical factor for the cardiac patient. A
single, nationwide emergency number for emergency serv-
ices—fire, police and health care—is essential, and the
number should be the same—911. Today, 911 covers 75%
to 80% of the population. There are two types of 911
systems available. One version is the phone number 911,
which connects the caller with an operator or dispatcher. A
more sophisticated version is the “enhanced 911” system,
which has automatic identification of the caller’s telephone
number and address. This has the advantage that the
information required for an emergency response is imme-
diately available. An enhanced 911 system throughout our
country should be a goal (187–192). Cellular and digital
telephones do not universally have location identification at
the present time.
Dispatch. Centralized dispatch is required to provide fast
and efficient EMS action. This is particularly important in
areas where there are multiple agencies providing services.
The dispatcher should be trained to determine what level
and extent of services are required. Dispatchers need to
quickly determine the nature of the emergency and the types
of equipment and personnel required and provide first-aid
(“prearrival”) instructions over the telephone. It has been
shown that untrained telephone callers can be instructed
and will perform cardiopulmonary resuscitation (CPR) until
the emergency rescuers can respond (190,191,193–198).
Levels of service. The Department of Transportation has
developed guidelines for training four different levels of
EMS personnel: 1) the first responder; 2) the emergency
medical technician (EMT), basic; 3) the EMT, intermedi-
ate; and 4) the EMT, paramedic (191,199–202).
First responders with 40 h of training do not transport
patients; they provide first-aid for most life-threatening
emergencies and may use automated external defibrillators.
Firefighters and security guards are often the first respond-
ers in the urban areas. In rural and smaller towns, law
enforcement officers and volunteers are often the first
responders providing treatment. They initiate therapy until
another more skilled person or team can assume care and
transport the patient (191,199–202).
A basic EMT (EMT-B) has about 120 to 150 h of
training in basic first-aid skills. An EMT-B is trained to
provide CPR, oxygen therapy and other types of first-aid
skills. Most ambulance personnel are EMT-Bs (191,199–
202).
The next higher level of training is the intermediate
EMT (EMT-I). The amount of training varies from state
to state. The Department of Transportation curriculum
requires about 450 to 600 h of training and is similar to that
of paramedics of a few years ago. The EMT-Is can usually
provide intravenous therapy, drug therapy, defibrillation and
tracheal intubation. These individuals provide service in
rural areas, where it is not feasible to have paramedics
(191,199–202).
The paramedic EMT (EMT-P) has the greatest extent of
training, ranging from 900 to 1,500 h. Paramedics are
trained to differentiate medical emergencies, provide defi-
brillation, administer cardiac drugs, infuse intravenous fluids
and do endotracheal intubation as well as care for many
other medical emergencies. Although EMT-Ps are less
common than EMT-Bs, they are responsible for transport-
ing the majority of patients in the U.S. (191,199–202).
Types of service. In the U.S., four major types of EMS
systems are utilized: city government– based systems,
hospital-based systems, public utility systems and competi-
tive private systems (32,76,190,191,199–206).
City government–based systems are most often through
the Fire Department. The Fire Department uses fire and
rescue officers as dual-trained personnel (fire and medical).
In some cities, the Fire Department provides both paramed-
ics and transportation; in others, it provides only paramed-
ics. The Fire Department may provide both basic treatment
and transport, as well as a paramedic service (a two-level
service system). The Fire Department has advantages by
employing personnel with more extensive training in dan-
gerous environments, extrication and rescue. The major
potential disadvantage of using the Fire Department is the
political environment in which it operates. Fire departments
compete for funding with other city services and even within
the Fire Department itself. There can be competition within
the Fire Department for resources, recognition and promo-
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tion, and at times there are hard feelings between firefight-
ers and EMS personnel. The civil service system can
sometimes make discipline difficult.
Police Department EMS systems are usually found in
smaller towns. These systems provide first-aid and trans-
port. Adjacent city services generally provide paramedic or
basic service with transportation. Often, an adjacent city
service is operated as a division of the city hospital. The
major advantage of this system is that it circumvents
intradepartmental politics and gives EMS the same empha-
sis as police and fire. A major cost may be housing and
locations for the emergency units and for a communications
system.
Another system is the hospital-based EMS system. These
are generally found in smaller towns where one or two
ambulances can service an area from the hospital. Some
towns provide a subsidy to the hospital to provide the
service.
The public utility model is one in which a single private
provider is given a virtual monopoly in exchange for services,
similar to that for public utilities. This service provides all
ambulance transport, including all contracts with health
maintenance organizations or preferred provider organiza-
tions, nonemergency transfers and emergency runs. The city
frequently has to pay less into this system because nonemer-
gency patient transportation is profitable. Patient charges
pay for the system rather than tax dollars.
The final model is the competitive private model. In this
model, competing companies either vie for business or are
centrally dispatched on a rotating basis. This tends to be the
least costly. However, response times can be long, and the
level of service may only be basic. This model can lack
coordination.
Public service versus business. The bulk of the public
service systems is usually paid by the taxpayer, with the
individual patient paying only a portion of the cost. Public
service systems tend to respond to the victim and obtain
only essential information. Thus, most public service sys-
tems only obtain adequate billing information for the
minority of patients. In contrast, public utility and compet-
itive private systems obtain funding from the patient, with
only a small subsidy coming from the city for indigent
losses. The bills are itemized with a response fee, a mileage
fee for transport and fees for any service rendered, similar to
a hospital and physician’s bill combined. These systems tend
to provide more billable services for a far greater number of
patients than do public service systems.
When a system is managed as a public service, there are
a number of differences in the service that may not be
noticed by the casual observer. A public service system tends
to offer uniform levels of service. A public service system will
position units so that response time is uniform for most
citizens. A system operated as a business will operate the
ambulances so that the load per ambulance is similar, which
may lead to longer response times in the periphery. Neither
the average response times nor the percentage of calls
handled within a period may reveal these differences, but
they could greatly affect some citizens.
Another difference between the two major approaches is
the problem of unusual load requirements. At the time of a
rain storm or disaster, business types of systems may not be
able to respond as promptly as a public service system, which
tends to staff for disaster. Fire Departments often have extra
personnel who can be moved quickly from fire suppression
to EMS should the need arise.
Business types of systems can respond more quickly to
changes in technology, because most new technology can be
billed. Because public service systems are a part of the
governmental bureaucracy, it can be difficult and time
consuming for them to add new technology.
Medical Direction
Strong medical direction must be present for all EMS
systems, regardless of the level of care provided, to ensure
that patients receive appropriate care and are taken to the
appropriate facility. This includes setting patient care stan-
dards through protocols. It also includes effective physician
or physician-directed input by means of radio or telephone
communications where indicated (190,191,200).
PREHOSPITAL ASSESSMENT
Prehospital identification of patients with AMI. The
primary purpose for prehospital 12-lead electrocardio-
graphic (ECG) diagnostic programs is the early detection of
AMI with ST segment elevation (207), and communication
of that information to the receiving emergency physician
before patient arrival. Multiple studies have shown the
feasibility of performing prehospital 12-lead ECGs
(208,219). Diagnostic-quality ECGs can be acquired and
successfully transmitted in about 4 min in ;85% of patients
eligible for 12-lead electrocardiography (210,211,215,216).
It has been demonstrated that prehospital 12-lead ECGs
improve prehospital diagnostic accuracy for patients with a
final hospital diagnosis of AMI, angina or nonischemic
chest pain (210). For patients with a final hospital diagnosis
of AMI in one study, the specificity of the base physician’s
prehospital working diagnosis (incorporating both
paramedic-acquired history and a prehospital 12-lead
ECG) was improved from 68% to 95%, and the positive
predictive value increased from 33% to 71%, as compared
with single-lead telemetry (210). When the 12-lead ECG
alone was used by base physicians to diagnose AMI,
sensitivity was 42%, specificity increased to 99.7% and
positive predictive value increased to 97%, demonstrating
that the prehospital 12-lead ECG alone was more accurate
in the prehospital diagnosis of AMI than the ECG and
historic information (210).
The direct impact that improved prehospital diagnostic
accuracy has on treatment and outcome for patients with
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AMI, angina and nonischemic chest discomfort remains to
be fully characterized.
Reduced hospital-based time to treatment. Many studies
have demonstrated significant reductions in hospital-based
time to treatment with reperfusion therapy for patients with
AMI identified before patient arrival (213,215,216,220).
Time savings in these studies ranged from 20 to 55 min
(213,215,216,220).
A similar time reduction was demonstrated by transmit-
ting the prehospital 12-lead ECG directly to the receiving
hospital (215). Different methods of patient transport and
communication of diagnosis have also been assessed (216).
The median hospital delay to treatment in one such study
was 64 min for patients transported by private automobile,
55 min for patients transported by local ambulance, 50 min
for patients transported by the EMS with a prehospital
ECG obtained but not transmitted to the receiving hospital
and 30 min for patients transported by the EMS with a
12-lead ECG transmitted from the field (216).
These data support the contention that prehospital iden-
tification of patients with AMI reduces hospital-based
door-to-drug time and assists receiving hospitals in meeting
the National Heart Attack Alert Program’s recommenda-
tion of treatment within 30 min of arrival (187).
The management and outcome of patients receiving and
not receiving prehospital 12-lead electrocardiography were
evaluated in the National Registry of Myocardial Infarction-2
data base (221). Although the median time from infarct
onset to hospital arrival was longer among those having a
prehospital ECG, this group experienced a significantly
shorter median time to initiation of either thrombolysis or
primary angioplasty. The prehospital ECG group was also
more likely to receive thrombolytic therapy, primary angio-
plasty or CABG. The in-hospital mortality rate was 8% in
patients with a prehospital ECG and 12% in those without
a prehospital ECG (p , 0.001). Investigators concluded
that the prehospital ECG is a valuable test that is under-
utilized nationally.
Identifying thrombolytic candidates by checklists. Pa-
tients with AMI identified by a prehospital 12-lead ECG
can be further classified as thrombolytic-eligible candidates
through the use of a checklist. Prehospital thrombolytic
therapy trials provide experience that appears to be useful in
reducing time to treatment (212,217,222–228). In the U.S.,
paramedics, not physicians, have used checklists to identify
thrombolytic candidates (209,215,219,220,229). One U.S.
study directly addressed the accuracy of a paramedic con-
traindication checklist (209). The positive predictive value
of case selection was 100%. Paramedic scene time was
increased by only an average of 4 min (209).
These data support the feasibility, accuracy and time-
effectiveness of prehospital identification of thrombolytic
candidates through focused contraindication checklists.
Such a checklist should be part of the prehospital assessment
of all patients with chest discomfort, as recommended in the
American College of Cardiology/American Heart Associa-
tion’s Guidelines for the Management of Patients with
Acute Myocardial Infarction (230).
Computerized ECG programs. Several computerized
ECG programs have potential to assist in improving pre-
hospital AMI diagnostic accuracy and clinical decision-
making.
Electrocardiographic criteria for the automated ECG
diagnosis of AMI has been evaluated using the 12-SL
interpretive algorithm (Marquette Medical Systems, Inc.)
(218). This automated program diagnosed acute evolving Q
wave myocardial infarction with 71% sensitivity and 98%
specificity. Specificity was 100% when patients with a
known previous Q wave myocardial infarction were ex-
cluded.
In another large study, the positive predictive values of
the computer- and physician-interpreted ECG were 94%
and 86%, respectively, and the negative predictive values
were 81% and 85% (231). Computerized ECG algorithms
are not all the same and should be prospectively validated
before implementation (232,233).
Predictive instruments. The Acute Cardiac Ischemia
Time-Insensitive Predictive Instrument (ACI-TIPI) has
been prospectively validated for use in the Emergency
Department (234) and retrospectively validated for prehos-
pital use (235). This predictive instrument is incorporated
into a computerized electrocardiograph. Using the patient’s
age, gender and presence or absence of chest discomfort on
presentation, the ACI-TIPI predicts the likelihood of acute
cardiac ischemia (AMI or angina), along with the ECG. In
one study, the ACI-TIPI was associated with a reduction in
false positive diagnoses and reduced the number of hospital
admissions among patients without acute ischemia (234).
PREHOSPITAL STUDIES OF FIBRINOLYTIC THERAPY
Several studies have reported results of trials of fibrinolytic
therapy initiated before hospital admission. Most have been
designed to evaluate time savings, resulting left ventricular
function, infarct size and mortality differences in patients
treated in the prehospital setting as compared with in-
hospital treatment. In an early, small, randomized Israeli
trial of prehospital versus in-hospital treatment aimed at
evaluating left ventricular function, there was no difference
in resulting ejection fraction despite a 43 min time differ-
ence between the groups. Mortality was also similar (228).
The findings from this, as well as other, studies led to
several randomized, controlled trials. The largest trial—the
European Myocardial Infarction Project (EMIP)—was car-
ried out in 15 European countries and Canada. Anistreplase
was given as a bolus in the prehospital setting to 2,750
patients, and their outcomes were compared with those of
2,719 patients treated in the hospital (222). Although the
project initially planned to enroll 11,000 patients to have
sufficient statistical power to show a 3% difference in
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mortality, recruitment was slow and the study was termi-
nated early. The prehospital treatment resulted in an aver-
age time savings of 55 min from the time of onset of
symptoms to initiation of treatment (130 min for the
prehospital group vs. 190 min for the in-hospital group).
Total mortality was reduced by 12% (p 5 0.08) and cardiac
mortality by 16% (p , 0.05) in prehospital-treated versus
hospital-treated patients. The greatest effect on mortality
was when treatment differences were .90 min between the
two strategies.
The Grampian Region Early Anistreplase Trial
(GREAT) was a study of 311 patients aimed at evaluating
prehospital-initiated fibrinolytic therapy, this time given by
general practitioners in patients’ homes as compared with
after hospital arrival. The average time to treatment was 101
versus 240 min, respectively. At three-month follow-up,
patients treated in the prehospital group had fewer Q wave
myocardial infarctions and had improved left ventricular
function (236). The one-year mortality was substantially
lower in the prehospital treatment group (10.4% vs. 21.6%,
p 5 0.007).
The Myocardial Infarction Triage and Intervention
(MITI) trial was the largest randomized prehospital trial in
the U.S. It included 360 patients who were initially screened
by paramedics utilizing a checklist and ECGs, which were
transmitted by cellular telephone to a base station physician
for the assignment of treatment. The trial only included
patients with a short time to treatment for chest discomfort
onset in both prehospital versus hospital initiated throm-
bolysis groups (92 vs. 120 min, respectively). The prehos-
pital treatment strategy, therefore, provided only a modest
time savings of 33 min. There was no significant difference
in complication rates between treatment strategies, suggest-
ing that paramedic-administered treatment could be safe.
The primary end point of the trial was a ranked composite
score that included death, stroke, serious bleeding and
infarct size measured by sestamibi imaging. The composite
score was similar for both strategies (53% vs. 54%), infarct
size (6.1% vs. 6.5%) and mortality (5.7% vs. 8.1%). To
further explore the effect of treatment time, a secondary
analysis was performed on all randomized patients. There
were marked differences in both infarct size and mortality
between patients treated within 70 min and those treated
between 70 min and 3 h (1.2% vs. 8.7%, p 5 0.04).
In a meta-analysis of the three major trials and from five
smaller trials, there was a significant reduction in mortality
among patients randomized to prehospital therapy (p 5
0.002). It was estimated that the benefit–time gradient at 35
days was 21 lives saved per thousand treated per hour (237).
These trials have suggested that when long delays of 60 to
90 min or greater are routine, then prehospital initiation of
fibrinolytic therapy should be considered. It is clear, how-
ever, that prehospital electrocardiography performed by
paramedics appears to reduce the total time to treatment
and allows for preparation of staff at the receiving hospital.
Most data also suggest that the time benefit of treatment is
not linear, and that the magnitude is much greater in
patients seen in the first hour as compared with 2 to 12 h
(238) (Fig. 1). Unfortunately, few patients present to
hospital within the first 60 to 90 min, making this strategy
less attractive. The current approach requires an extensive
expenditure of resources and organization for the benefit of
a relatively small fraction of patients. Hospitals have mark-
edly reduced the time to treatment in recent years from
hospital arrival to thrombolytic therapy, whereas symptom
onset to hospital arrival was unchanged at 2.4 h in the
Global Use of Strategies to Open Occluded Coronary
Arteries in Acute Coronary Syndromes trials over a seven-
year period (182). Similar observations were made in the
National Registry of Myocardial Infarction registry in over
250,000 patients treated with fibrinolytic therapy over a
five-year period. Some studies have recently shown that
treatment times are now in the neighborhood of 15 to
20 min. Both the EMIP and MITI trials have shown a
substantially declining benefit of fibrinolytic therapy as a
function of time. They provide community emergency
services and hospitals an impetus for improving critical care
delivery to patients with AMI.
REGIONAL PLANNING
Regional plans should be established to determine the
manner of delivering emergency cardiac services. These
plans should integrate the uses of various emergency re-
sources, including both prehospital and hospital resources.
The regional plan should set out the appropriate criteria
of how a patient is allocated to a particular hospital. Many
systems currently require that the patient be taken to the
closest facility. Other systems take the patient to the
hospital of the patient’s choice, as long as the system has the
necessary resources to provide transport to another facility
and the patient is stable. These simple policies fail to take
into account how they affect the delivery of optimal care to
Figure 1. From Fibrinolytic trialists collaboration. Lancet 1994;
343:311–20.
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the cardiac patient. Transport to the closest facility may not
be appropriate if the patient has been recently cared for at
another facility or is at high risk of complications after
myocardial infarction. In contrast, the closer facility may be
able to provide care more quickly. Hospital crowding and
bed availability should also be considered in the plan. These
competing concepts must be considered in the planning
process. A triage plan is particularly important for patients
at high risk of death.
The hospital facilities in many urban and suburban areas
vary widely, with some providing 24 h full tertiary cardiac
services, others having inconsistent staffing with a catheter-
ization laboratory but no surgery on site and still others
having no tertiary cardiac services. Coronary care units, on
the other hand, are common in all areas. The logical
question, therefore, is should patients with AMI be diverted
to places with full tertiary cardiac services? Unfortunately,
this question has not been studied directly in any great
detail. Throughout the U.S., patients with trauma are
diverted depending on the severity of the illness and
resources of the recovery hospital. This severity is gauged
through assessment of various factors associated with type of
injury as well as the initial clinical findings. Previous studies
of elderly (Medicare) patients have suggested that the initial
early treatment of AMI within the first day was the major
determinant of survival at four years. In addition, this study
showed that patients who lived within 2.5 miles of a hospital
with cardiac catheterization facilities were substantially
more likely to be admitted to a high volume AMI hospital
(67% vs. 37%) and to undergo cardiac catheterization within
seven days (21% vs. 11%), with a 1% absolute lower rate
mortality at one year, as compared with patients living .2.5
miles away (239). These findings have been strengthened by
the observations that patients admitted to a high volume
hospital (.1.4 AMIs per week) had a lower mortality at one
year (27% vs. 30%) than those admitted to a lower volume
hospital (,1.4 AMIs per week). These findings were
consistent across a variety of high and low risk criteria, but
were not associated with a greater use of revascularization
(240). However, the link between outcomes after AMI may
be closely related to the more appropriate use of “evidence-
based medicine” rather than the technology used (241).
Large, randomized trials of thrombolytic therapy have
shown that the 30-day and one-year mortality rates are
closely related to certain baseline characteristics such as age,
blood pressure, heart rate and signs of heart failure (167).
The overall 30-day mortality rate from a variety of trials has
been between 5% and 10%, whereas in certain subgroups the
mortality has been substantially higher (Table 2) (242–244).
For patients with cardiogenic shock, the mortality has
remained .50% in the majority of studies and has not
changed over time (245). The same risk factors described
earlier are also predictive for the development of cardiogenic
shock, which typically occurs within the first 6 to 12 h after
arrival to the hospital. These findings suggest that certain
patient groups with heightened risk can be easily identified
by simple measures.
Although individual randomized trials of thrombolysis
versus primary PTCA have been done, a meta-analysis of
the available data suggests that primary PTCA may be most
advantageous among high risk patients (as defined earlier).
The outcomes comparing one-year mortality from the
meta-analysis (246) suggest particular benefit with primary
PTCA among the high risk patients (Table 3).
Patients with cardiogenic shock represent the highest risk
group. A prospective, randomized trial has identified a trend
toward a reduction in 30-day mortality in patients random-
ized to emergency revascularization within 6 h of onset of
shock as compared with a conservative approach (247). The
benefit was seen across all groups, but was particularly
apparent in patients ,75 years old (41% vs. 57%). On the
basis of these observations, it would appear that high risk
patients with AMI should be triaged to a high volume AMI
center that routinely (24 h service) offers emergency revas-
cularization (PTCA and CABG) if the facility has a
transport time of #30 min.
CONCLUSIONS AND RECOMMENDATIONS FOR
PATIENTS WITH ACUTE CORONARY SYNDROMES
1. Public and professional education should be imple-
mented to increase early recognition of symptoms,
Table 2. Mortality Rates of Subsets of patients in Randomized
Trhombolysis Trials
Variable FTT GUSTO-1 GUSTO-3
Age .75 years 25% 21%2 20%
HR .100 beats/min 20% 16% 18%
BP ,100 mm HG 28% 16% 18%
Diabetes 14% 11% 12%
BP 5 blood pressure; FTT 5 Fibrinolytic Therapy Trialists; GUSTO 5 Global Use
of Strategies to Open Occluded Coronary Arteries in Acute Coronary Syndromes;
HR 5 heart rate.
Table 3. Mortality Rates for the Two Forms of Reperfusion as
Determined in a Meta-analysis of Randomized Trials (From
Primary Coronary Angioplasty Thrombolysis Collaboration)
Variable
Primary
PTCA Thrombolysis
Anterior infarct location 8% 15%
Age .70 years 13% 24%
Previous MI 10% 23%
Diabetes 9% 19%
MI 5 myocardial infarction; PTCA 5 percutaneous transluminal coronary angio-
plasty.
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reduce patient delay and enhance appropriate use of
EMS systems.
2. The physician should ensure that those patients at risk
for an acute coronary syndrome know when and how to
react to their symptoms. Risk factor modification
should be achieved for all patients.
3. When there is an emergency such as cardiac arrest,
chest discomfort or other signs of acute coronary
syndromes, 911 should be called directly and should be
nationally available as the only emergency call number.
4. The 911 and EMS calls through cellular or digital
telephones should have priority over nonemergent calls.
5. All types of telephones should have location identifica-
tion that is transmitted to the 911 center.
6. All EMS dispatchers should be trained in medical
dispatching, including prehospital instructions.
7. Communities should develop plans to optimize triage
and treatment of patients with acute coronary syndromes.
8. The EMS providers should use a prehospital chest
discomfort checklist.
9. Prehospital 12-lead ECG programs should be imple-
mented in established urban and suburban paramedic
systems.
10. Prehospital 12-lead ECG programs should communi-
cate the prehospital findings to the receiving emergency
physician before patient arrival.
11. Prehospital 12-lead computer-interpreted ECGs and
predictive instruments should be prospectively validated.
12. Patients with myocardial infarction and hemodynamic
compromise, cardiogenic shock or other high risk
criteria should be triaged to medical facilities that have
24 h staffed cardiac care services that include emergency
revascularization (percutaneous coronary intervention
and CABG) and hemodynamic support available, pro-
vided ambulance transport duration is not excessive
(.30 min). Triage should be performed as soon as
possible, preferably in the field or in the nearest
Emergency Department, depending on the medical
community.
13. Routine prehospital thrombolytic therapy is currently
not warranted, except possibly in systems with long
transport delays and experienced EMS teams.
Task Force 2: Acute Coronary
Syndromes: Section 2B—Chest
Discomfort Evaluation in the Hospital
Adolph M. Hutter, Jr., MD, MACC, Co-Chair, Ezra A. Amsterdam, MD, FACC, Co-Chair,
Allan S. Jaffe, MD, FACC, Co-Chair
RATIONALE
Reliable, cost-effective management of patients presenting
to the Emergency Department (ED) with chest pain re-
mains a major clinical challenge. There are over five million
annual visits to EDs in the U.S. for this problem, resulting
in two million hospital admissions at a cost of $8 billion
(248), and three-fourths of these admissions for presumed
myocardial ischemia or infarction prove to be incorrect
(249). The primary goal in the management of patients
presenting with chest pain is rapid recognition and man-
agement of a cardiac ischemic event. Secondary goals
include assessment of risk in patients with suspected isch-
emia and minimization of unnecessary admissions for low
risk conditions. Because of the focus on patient welfare and
the litigation potential for failure to detect myocardial
infarction (MI), a low threshold for admission has been
applied in these patients, but 2% of patients with MI are
discharged inadvertently, and the morbidity and mortality of
this group are substantial (250). Underscoring this problem
are data indicating that failure to diagnose MI has been the
leading cause of medical malpractice awards against ED
physicians (251).
Nontraumatic chest discomfort remains the primary
stimulus triggering evaluation of patients for possible acute
coronary syndrome (ACS) in the ED. The ACSs include
unstable angina, non–Q wave MI and Q wave MI. To be
included in the American College of Cardiology registry for
ACS, ST segment changes must be present. However, for
this report, ACS includes those patients with suggestive
clinical presentations and/or positive biomarkers with or
without ST segment changes (252). The clinician in the
emergency setting must be suspicious, however, of atypical
presentations for ACS. It is essential that emergency phy-
sicians be able to make a rapid, carefully focused clinical
assessment to identify patients with ST segment elevation
MI. Of patients presenting to the ED with chest pain,
;95% do not have electrocardiographic (ECG) evidence of
evolving Q wave MI, and only 20% will ultimately have
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evidence of unstable angina or non–Q wave MI (249). After
the initial evaluation, including a directed history, physical
examination and 12-lead electrocardiogram other methods
must be used by the clinician to detect ACS in the ED. If
the 12-lead ECG is nondiagnostic for ST segment elevation
acute MI, patients with a possible ACS must be evaluated
for 1) myocardial necrosis; 2) rest ischemia; or 3) exercise-
induced ischemia (253). Many hospitals have developed a
protocol-driven approach to achieve these objectives
(254,255). Through efficient evaluations that take 6 to 12 h,
myocardial necrosis is detected by cardiac biomarkers; rest
ischemia is documented by serial ECG or ST segment trend
monitoring and, if needed, echocardiographic or radionu-
clide studies; and exercise-induced ischemia is assessed by
exercise testing, stress echocardiography or radionuclide
testing.
A comprehensive, protocol-driven approach is essential
because it minimizes variability in diagnosis and treatment
of ACS and promotes optimal management. The evaluation
must be complemented by careful documentation of diag-
nostic results and treatment. Communication with the
patient’s primary physician is essential to ensure appropriate
evaluation and treatment in the ED, and care must also be
coordinated with the cardiovascular specialist, when appro-
priate.
Evaluation in the hospital ED or chest pain center
(CPC). Chest pain centers or programs were initially de-
veloped to facilitate therapy for patients with acute MI and
other ACSs (253,256–259). Their number has grown
continuously, and they have subsequently evolved to include
safe, cost-effective management of low risk patients present-
ing with chest pain. It was recently estimated that 30% of
hospitals in the U.S. have these units, which number
;1,200 (256).
The rapid increase in CPCs was stimulated in the early
1980s by the need to reduce time to coronary reperfusion
therapy (257). The necessity for safer, more cost-effective
management of low risk patients, who comprise the major-
ity presenting to the ED with chest pain, has been a major
factor in their continuing growth (206,260–262).
Chest pain units vary in form and may be based more on
process and coordination of skilled personnel (cardiologists,
emergency physicians and nurse specialists) and availability
of dedicated equipment than on physical structure. Empha-
sis is on protocol-based, systematic management to promote
optimal application of current standards of care. Guidelines,
or critical care pathways, are commonly employed. There
are few controlled trials on the utility of CPCs in the
management of high risk patients, but the importance of
rapid coronary reperfusion therapy is incontrovertible. Re-
cent data demonstrate the efficacy of achieving this objective
with a chest pain unit strategy (263). In addition, the
importance of early stratification of patients into high and
low risk groups is emphasized in the first published guide-
line for the management of unstable angina (264).
The emphasis of CPCs is variable. Some focus on high
risk patients, whereas others primarily aim to decrease
unnecessary admissions of low risk patients. In addition to a
directed history, physical examination and administration of
aspirin, current recommendations include ECG acquisition
and interpretation within 10 min to detect myocardial
ischemia and make a decision regarding coronary reperfu-
sion therapy, which should be initiated within 30 min of
presentation in appropriate patients (188,265,266). Many
clinicians advocate briefer time limits for assessment and
initiation of therapy (e.g., ,20 min). Patients with non–ST
segment elevation ischemic syndromes also require prompt
identification and treatment. These two groups of patients
are recognized as high risk and are transferred to the
inpatient service for further management.
In contrast, low risk patients with chest pain, character-
ized by a stable clinical status and a normal or nondiagnostic
ECG, have been increasingly managed by a variety of
accelerated diagnostic protocols, usually 6 to 12 h of
monitoring and serial cardiac biomarkers (254). If this
evaluation is negative, exercise testing (or another noninva-
sive cardiac stress study) is usually performed, and the
patient is discharged if there are no abnormalities. Multiple
techniques are currently being assessed for detection of
myocardial ischemia during accelerated diagnostic proto-
cols. These include innovative ECG methods, clinical
algorithms, new biomarkers, noninvasive cardiac imaging
and immediate exercise testing (255). It has been amply
demonstrated that accelerated diagnostic protocols utilizing
one or more of these techniques in patients identified as low
or intermediate risk on the basis of their initial presentation
are safe and accurate. Length of stay has been consistently
reduced, and subsequent risk in patients with negative
evaluations is low. Initial data suggest this strategy is
cost-effective, but controlled studies are few, and it is
recognized that this approach has the potential for overuti-
lization of expensive tests.
Link between the “chest pain ED movement” and the
chest pain awareness educational program. One goal of
the “Chest Pain ED Movement” has been development of a
partnership between emergency physicians and cardiologists
in a continuous quality-improvement process to enhance
delivery of heart attack care through community penetration
that links the CPC with an early symptom community
awareness program. A major focus of this strategy is
addressing reasons for delay when patients are having early
symptoms. One focus should be on patients presenting with
central chest discomfort, not necessarily perceived as chest
pain, as well as those with chest pain. Thus, the CPC
movement is a strategy to reduce the time to treatment in
patients with evidence of early active ischemic heart disease.
The new paradigm, as seen in this light, represents a shift in
care to enhance present day management of patients with
ischemic heart disease.
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Operational plan of the CPC. The development and
effective operation of a CPC require coordination at multi-
ple levels within the institution, including 1) administrative
support (budget, personnel); 2) development of a protocol
by emergency physicians, cardiologists and nurses; and 3)
integration of special services such as exercise testing,
nuclear cardiology, echocardiography and pharmacy. Of
primary importance, optimal management in CPCs is
critically dependent on communication between the cardi-
ologists and ED physicians.
STAFF. The location of the CPC typically determines the
mix of personnel needed to staff the unit. If it is contiguous
with the ED, emergency nurses often staff the program.
This requires a nurse to patient ratio of approximately 1:4,
similar to that of noncritical care areas of the ED or a
coronary care unit (CCU) step-down unit. Special training
of emergency nurses is necessary before working in a CPC
environment. This may include information regarding bio-
markers, serial 12-lead electrocardiography or ST segment
trend monitoring, exercise testing, echocardiography and
radionuclide testing. The CPC stay is also an excellent
opportunity to educate patients about ACS, risk factors and
the importance of timely follow-up with a cardiologist or
other appropriate physician if the evaluation is negative.
Nurse practitioners and physician assistants may help to
staff CPCs, but decisions to treat, admit or release the
patient require physician involvement in every step of care
and are the responsibility of the attending physician. Tech-
nicians who perform studies such as echocardiography or
nuclear cardiology are essential and must have the flexibility
to follow protocols. The availability of technicians at night
or on weekends determines not only the frequency of
testing, but also the ability of a CPC to extend service
beyond the traditional scheduling limits.
PHYSICIANS. If the CPC is located in or next to the ED,
emergency physicians are responsible for evaluating and
monitoring patients, administering therapy and developing
disposition plans for hospital admission or discharge. The
CPC requires 15 to 20 patients at a time to justify the
presence of a dedicated emergency physician at all times.
Smaller CPCs are usually served by physicians with other
responsibilities in the ED. Typically, two or more physi-
cians working simultaneously in the ED are necessary to
allow sufficient free time to attend to patients in the CPC.
In CPCs in or next to the ED, emergency physicians
monitor symptoms and signs, interpret diagnostic tests and
initiate therapy for patients admitted with ACS. As a
functional component of an ED, the availability of an
emergency physician 24 h per day, seven days per week
remains an essential component. Offline discussions regard-
ing protocols with referring physicians, clinical pathologists
and cardiologists ensure a consistent approach to evaluation,
treatment, patient education and follow-up plans for pa-
tients discharged. Such communication with cardiologists
allows a coordinated approach to administering antiplatelet
and antithrombotic agents, nitroglycerin and beta-blockers
in a protocol-driven manner. For patients with ST segment
elevation consistent with acute MI, fibrinolytic therapy is
usually administered without previous consultation with a
cardiologist. In hospitals where primary angioplasty is avail-
able, communication with the interventional cardiologist is
necessary to decide between thrombolysis and primary angio-
plasty and to coordinate mobilization of the cardiac catheter-
ization laboratory team if the latter therapy is selected.
In institutions where the CPC is located in the CCU or
serves as a part of an inpatient step-down unit, cardiologists
(or internists) are responsible for serial examinations, inter-
pretation of diagnostic testing and, if such testing is positive
for an ACS, therapeutic directives.
For CPCs adjacent to the ED or CCU, cardiologist
involvement in the care of the patient at the end of a 6 to
12 h protocol is often necessary to interpret predischarge
tests such as exercise electrocardiography or imaging. The
decision to admit a patient to the hospital or discharge the
patient often requires the collaboration of the cardiologist
and the physician responsible for the patient in the CPC. In
institutions without a structurally designated CPC, the
goals of this strategy can be implemented by adhering to
protocols that focus and coordinate the efforts of the diverse
personnel noted earlier to provide optimal management of
patients presenting with chest pain. In this approach, the
CPC process remains foremost.
INITIAL TRIAGE
The goals of clinical assessment of the patient with chest
pain are 1) to distinguish those patients with ischemia or
infarction from those with other potentially serious (aortic
dissection, pericarditis, pulmonary embolism) or less serious
causes of chest pain; 2) to assess the risk of early adverse
outcomes in patients with suspected ischemia or infarction;
and 3) to initiate therapy rapidly in patients with serious
clinical conditions. Initial evaluation of the patient with
chest pain includes a careful history and physical examina-
tion and, in almost all cases, an ECG. It may be performed
by emergency medical service personnel, the triage nurse,
physician or other medical personnel. The evaluation may
begin at home, at the work site or another location and
continue during transfer and in the ED or outpatient
facility. Patients with probable ischemic pain and patients
with high risk features such as severe or prolonged pain or
hemodynamic compromise should be transported to the ED
by ambulance. Proper assessment at this point is critical to
the efficacy and cost-effectiveness of subsequent testing.
Differential diagnosis of chest pain. Until recently, the
description of the characteristic pain of myocardial ischemia
was based almost exclusively on data from men. However, a
number of patient groups commonly present with “atypical”
symptoms. In women, ischemia may be manifested by
symptoms such as fatigue, dyspnea or epigastric pain. Other
groups commonly presenting with atypical symptoms in-
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clude diabetics and the elderly. These factors must be
incorporated into the clinical evaluation.
CORONARY ARTERY DISEASE (CAD). The key factors in
recognizing ischemia in the ED are the characteristics of the
symptoms, the ECG, a history of CAD and evidence of
hemodynamic or electrical instability. The presence of
coronary risk factors may be a helpful predictor, but is of
limited utility and may even be misleading in this setting, as
compared with other variables such as the ECG. However,
in the absence of strong clinical or ECG evidence of
ischemia, assessment of risk factors has value. The discom-
fort or pain of myocardial ischemia or infarction is generally
described as tightness, heaviness, pressure, burning, aching,
squeezing, constriction or “indigestion.” It usually comes on
gradually over a minute or two and lasts minutes rather than
seconds. It is usually not affected by respiration or changes
in position. It is usually felt in the central chest, with other
common sites including the throat, jaw, back, epigastrium,
left chest and arm (usually left). Associated symptoms
include sweating, dyspnea, nausea, vomiting, lightheaded-
ness, weakness and malaise.
Typical angina is precipitated by physical or emotional
stress and is relieved by rest. The discomfort of stable angina
(most often not described as pain) is often relieved or
lessened within 2 to 5 min of the administration of
sublingual nitroglycerin. Ischemic pain due to infarction
may not be relieved by nitroglycerin. On physical examina-
tion, particular attention should be directed to signs of
pulmonary congestion and the presence, during symptoms,
of an S3 or paradoxic splitting of S2 (sign of systolic left
ventricular dysfunction), an S4 (sign of diastolic dysfunc-
tion) or a murmur of mitral regurgitation (sign of papillary
muscle dysfunction). Peripheral pulse deficits, or bruits, are
valuable clues to the presence of atherosclerosis, aortic
dissection or, rarely, vasculitis.
Electrocardiographic tracings should be obtained when-
ever possible in both the presence and absence of chest pain.
The ECG should be examined for evidence of a previous
MI. ST segment elevation $1 mm is generally indicative of
acute MI, but must be distinguished from other conditions
(e.g., early repolarization, pericarditis). Lesser degrees of ST
segment elevation are less specific for MI. Any ST segment
or T-wave abnormalities that are observed in the presence
but not in the absence of chest pain are suggestive of
myocardial ischemia. Peaked T-waves may be due to hy-
perkalemia or may be a hyperacute manifestation of isch-
emia. Fixed ST segment and T-wave abnormalities are
usually less specific, but are suggestive of myocardial isch-
emia or infarction if there is $1 mm ST segment depression
or elevation or deep symmetrical T-wave inversion. In
contrast, a normal ECG does not reliably exclude the
diagnosis of myocardial ischemia (or even infarction). It is
often helpful, and in some clinical presentations essential, to
obtain frequent serial ECGs (266).
PERICARDITIS. Pericarditis may occur in patients with con-
nective tissue disease, malignancy, previous radiation, recent
MI or thoracotomy or uremia or in previously healthy
individuals. The pain is usually sharp, midcentral in location
and worsened by inspiration or lying down. It may be felt in
the left chest, supraclavicular area, shoulder and, rarely, the
back. Fever may be present; difficulty taking a deep breath
should be distinguished from true dyspnea. A two- or
three-component pericardial friction rub is pathognomonic
of pericarditis. Pulsus paradoxus and jugular venous disten-
tion suggest pericardial tamponade. Diffuse ST segment
elevation, as well as PR segment depression, strongly
supports the diagnosis of acute pericarditis. Further evalu-
ation includes a chest radiograph and echocardiogram.
AORTIC DISSECTION. Patients with hypertension, Marfan’s
syndrome, trauma or bicuspid aortic valve or previous aortic
valve surgery and those who are pregnant are at risk for
dissection of the thoracic aorta. The pain of dissection is
usually abrupt in onset and is often described as ripping or
tearing, but may be similar to the pain of myocardial
ischemia. It is located in the chest or back, or both, and may
radiate to the teeth. Associated symptoms are related to
affected branches of the aorta and include angina, dizziness
and other neurologic complaints. Physical examination may
reveal unequal arm blood pressures, pulsus paradoxus (due
to associated cardiac tamponade), signs of left pleural
effusion, aortic insufficiency and pulse deficits. The ECG
may reveal myocardial ischemia (usually in the distribution
of the right coronary artery). When the initial assessment
suggests aortic dissection, imaging with chest radiography,
transesophageal echocardiography, computed tomography
or magnetic resonance imaging, or a combination of these,
is appropriate. Fibrinolytic therapy should not be initiated if
the diagnosis of aortic dissection is being considered seri-
ously in the differential diagnosis.
PULMONARY EMBOLISM. Patients at risk for pulmonary
embolus include those with pelvic or leg trauma, previous
surgery, immobility, obesity and hypercoagulable states.
“Pleuritic” chest pain results from pulmonary infarction.
Substernal pressure or discomfort may be due to right
ventricular ischemia resulting from an increase in pulmonary
vascular resistance and a decrease in systemic arterial pres-
sure, and thereby coronary perfusion pressure. Tachypnea
and tachycardia are common findings. In the presence of
massive pulmonary embolus, the ECG may show an S1-Q 3
pattern, a rightward axis and right precordial T-wave
inversions. Further evaluation may include a V˙Q scanning,
contrast spiral computed tomographic scanning, pulmonary
angiography and noninvasive evaluation of leg veins. Unless
there is a contraindication, heparin is begun when the
diagnosis is first discussed.
OTHER CAUSES OF CHEST PAIN. Exertional (and, rarely,
rest) angina can occur in patients with aortic stenosis,
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hypertrophic cardiomyopathy, pulmonary hypertension or
pulmonic stenosis. Chest pain may be caused by a thoracic
aortic aneurysm, pleuritis and pneumothorax. Of several
gastrointestinal causes of chest pain, esophageal spasm is
noteworthy in that it may be relieved by nitroglycerin. The
pain of herpes zoster may bring patients to medical atten-
tion before bullae appear. Various musculoskeletal disorders,
including arthritis of the cervical spine, costochondritis and
chest wall muscle injuries may cause pain that mimics
angina. Careful palpation of the chest wall may indicate
point tenderness and reproduce the patient’s presenting
symptom.
LOW RISK PATIENTS
The low risk population can be readily recognized in most
cases from the initial clinical presentation and the ECG.
Patients with chest pain with a risk of MI ,5% and a risk
of cardiac complications ,1% can be identified by this
approach (267). Patients with negative findings after eval-
uation in the CPC of the ED usually have noncardiac
etiologies of their symptoms and often require further
outpatient studies to determine the cause of their symptoms
so that appropriate therapy can be initiated. It is essential
that further evaluation be done in conjunction with the
patient’s primary physician. Noncardiac conditions (e.g.,
gastrointestinal, musculoskeletal, pulmonary, psychological)
may be responsible for chest pain symptoms that initiate a
cardiac evaluation. Too often, evaluation ends with the
negative cardiac workup. Identification of the etiology of
symptoms in this sizable group of patients has the potential
to ameliorate the patient’s problem and avoid unnecessary
return to the ED. In some patients, even the most thorough
evaluation for noncardiac sources of pain is unrevealing.
These patients rarely have a life-threatening problem, but
their symptoms may be disabling. A physician expert in pain
management may be helpful in such cases. Up to 40% of
patients with a negative workup have chest pain related to
panic attacks. This is infrequently recognized by physicians
during the acute episode and on follow-up (268). Somati-
zation syndrome (multiple symptoms across organ systems
without an organic basis) is a relatively common noncardiac
cause of chest pain in patients presenting to the ED. If
patients meet the Diagnostic and Statistical Manual of
Mental Disorders IV (DSM-IV) (269) criteria for diag-
nosis, consideration of cardiac disease should be based on
objective findings. Other patients with nonischemic pain
may have what has recently been termed the “sensitive
heart,” in which normal physiologic stimuli (e.g., changes
in intracardiac pressure, blood flow and heart rate) are
sensed as discomfort or pain in the chest (270). In
contrast, some patients with chest pain have myocardial
ischemia with angiographically normal coronary arteries
(syndrome X) (271).
ASSESSING LEVELS OF RISK
AND APPROPRIATE INITIAL
MANAGEMENT IN PATIENTS WITH MYOCARDIAL
ISCHEMIA OR INFARCTION (HIGH RISK PATIENTS)
Once the diagnosis of myocardial ischemia or infarction is
made, the clinician must assess the history, physical exam-
ination and ECG to determine 1) the pace of initial therapy,
including acute reperfusion strategies, if indicated
(266,272); and 2) the appropriate next step in evaluation if
reperfusion therapy is not indicated.
Appropriate patients with ST segment elevation MI
should receive coronary reperfusion therapy. Selected high
risk individuals with non–ST segment elevation ACS
should be admitted for intensive medical management or
coronary angiography (264,266,272).
INTERMEDIATE RISK
PATIENTS: FURTHER EVALUATION
Continuous ST segment ECG monitoring and non-
standard ECG lead systems: use in patients with chest
pain who present to the ED. The rest 12-lead ECG is the
standard of care in the diagnosis of patients with chest pain
seen in the ED. Approximately 50% or less of patients with
acute MI or ACS initially have a positive 12-lead ECG.
Because early diagnosis is crucial to myocardial salvage,
newer strategies have been advocated for increasing the
sensitivity of the 12-lead ECG. These include serial elec-
trocardiography, continuous ST segment ECG monitoring
and the use of nonstandard lead systems, including posterior
and right ventricular leads. Recommendations for the use of
newer diagnostic technologies should rely on prospective,
randomized studies that 1) clearly show an incremental
benefit in terms of either diagnosis or prognosis; 2) take into
account the availability, ease of use and applicability; and 3)
demonstrate cost-effectiveness. Sensitivity and specificity
are important measures of a diagnostic test, but positive and
negative predictive values, which are highly dependent on
the prevalence of disease in the population tested, are more
important in determining the incremental value of a new
test or procedure.
STANDARD ECG. A 12-lead ECG should be obtained on
admission and repeated in 15 to 30 min if there is high
suspicion of myocardial ischemia or if there is recurrent
chest pain. In patients with negative accelerated diagnostic
protocols, a repeat ECG should always be obtained before
stress testing.
CONTINUOUS ST SEGMENT MONITORING. This technique
for detecting ischemia has been studied predominantly in
patients with established CAD. Its role in the detection of
myocardial ischemia in patients who present to the ED is
unclear. In one recent study in a CCU setting (with a high
prevalence of CAD), there was a 40% false positive rate of
ST segment shift. With the lower prevalence of CAD in
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most patients with chest pain who present to the ED, this
high incidence of false positive tests would be expected to
reduce the positive predictive value of this method. In
another study, the sensitivity for detecting acute MI and
ACS was increased from 55.4% to 68.1% using continuous
ST segment monitoring as compared with the initial ECG,
with a corresponding increase in the likelihood ratio of 10.3
to 13.1. In one additional study performed in a CPC/ED
protocol, the sensitivity of serial ST segment monitoring
was 21.2%, and the positive predictive value was 64.7%.
However, its additive value was unclear. In summary, the
cost-effectiveness of ST segment monitoring used in concert
with other measures has not been assessed directly, and thus
its role in the ED for patients with chest pain is uncertain.
RIGHT-SIDED ECG LEADS. The sensitivity of the standard
12-lead ECG in diagnosing right ventricular and posterior
infarction is extremely low. These limitations have given rise
to the evaluation of a number of nonstandard lead place-
ment systems. The most common of these are right ven-
tricular leads, of which the most sensitive is V4R. The
sensitivity and specificity for diagnosis of right ventricular
infarction with the V4R lead is ;80% during the initial 24 h
of infarction. A number of prospective studies have dem-
onstrated that right ventricular MI is a significant negative
prognostic factor in patients with coexistent inferior wall
MI. A V4R lead should be recorded at least once, as early as
possible, in all patients with inferior or inferoposterior wall
MI.
POSTERIOR LEADS. The 12-lead ECG is least sensitive for
detection of posterior ischemia in the distribution of the left
circumflex coronary artery (273). The use of leads V7
through V9 offers incremental benefit for diagnosing poste-
rior MI. The use of posterior ECGs leads V7 through V9 is
appropriate if there is suspicion of posterior infarction. It
cannot be recommended routinely for all patients presenting
to the ED with chest pain.
Biomarkers of cardiac injury for the treatment of low risk
patients. Two strategies have competed in this area. The
first relies on two markers—a rapid rising marker and a
marker that takes longer to rise but is more specific. This
strategy is predicated on the assumption that early diagnosis
of MI will change care by:
1. Facilitating identification of patients who may be candi-
dates for aggressive intervention.
2. Streamlining and improving flow within the CPC/ED
setting.
3. Providing the ability to discharge patients earlier.
4. Facilitating the triage of patients who are admitted to
various parts of the hospital.
Both myoglobin and isoforms of creatine kinase, MB
fraction (CK-MB) have been proposed for this purpose. In
the latest trial to date, no statistically significant differences
were observed between these markers (274). Myoglobin is
rapidly released from the myocardium and therefore is often
elevated in the first sample after presentation. Definitive
inclusion of infarction takes at least 6 h (274). The failure of
myoglobin to change over time by some predetermined
amount effectively excludes evolving infarction (275).
Isoforms of creatine kinase function on a different prin-
ciple. Low levels are present in the blood normally. Thus,
sensitive detection of a change can achieve earlier diagnosis.
This strategy allows the early identification of patients
without infarction who may need stress testing or other
follow-up evaluation. Individuals in whom biomarker levels
are increasing require additional sampling for either
CK-MB or troponin so that a definitive diagnosis of
infarction can be made with markers that have a higher
degree of specificity. Both myoglobin and CK-MB isoforms
lack tissue specificity. Thus, subsequent samples to diagnose
infarction may be needed at 6 and often 9 to 12 h. These
samples also allow detection of a subset of patients who may
have small amounts of necrosis as documented by a sensitive
marker like troponin. This group may have had cardiac
insults in the days before admission or a minimal amount of
myocardial necrosis more sensitively detected by troponin.
Regardless of the mechanism, this group is known to have
an adverse short- and long-term prognosis (276–279), and
preliminary data suggest that these patients may benefit
from more intense therapy (280). Although CK-MB is
frequently used at present for definitive “late diagnosis,”
eventually the troponin markers will replace CK-MB for
this purpose.
The troponins (cardiac troponins I and T) are a new class
of markers that have unique cardiac specificity (281). It is
now clear that for both markers, elevations are indicative of
cardiac injury only. In addition, at the present levels of assay
sensitivity, the troponins are more sensitive than CK-MB
for minor myocardial necrosis (282). Furthermore, continu-
ing release of troponin occurs for many days or even weeks
after cardiac injury (283). Inpatients who are at high risk for
ischemic heart disease (e.g., patients with unstable angina,
elevations) almost always have ischemic injury, and multiple
studies have confirmed that elevations presage an adverse
short- and long-term prognosis (276–279). Elevations are
more problematic in low risk patients. Hamm et al. (284)
have shown that elevations identified all of the patients at
risk in a cohort of 733 patients with chest pain and
nondiagnostic ECGs. Other investigators have shown a
significant relation between positive troponins and under-
lying, severe CAD in otherwise low risk patients in the
CPC (285). Elevation of troponins may also occur in a
second group of patients who have nonischemic cardiac
injury related to a transitory or chronic process. Thus,
elevations in low risk patients would not always be associ-
ated with CAD.
The second strategy suggests that the urgency is less
critical than suggested by the first strategy (286). The tactic
involved is simply to measure a single CK-MB or cardiac
troponin, with the understanding that definitive exclusion
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or inclusion of infarction will take longer. At present, for the
troponins, it appears that at least 9 h is required, depending
on the cutoff value utilized, and for CK-MB, the general
time is 12 h. These times can be altered somewhat by
choosing different critical values for diagnosis. The logic of
this strategy insists that marker proteins will not facilitate
the evaluation of patients in need of an immediate inter-
vention, because most of these patients present with clinical
syndromes and ECG changes that are easily identified. It
further argues that discharge and in-hospital triage will not
suffer substantially from a 2 to 3 h delay. The advantage of
this strategy is that it is definitive in both directions (to
include and exclude infarction).
The strategy suggested by Hamm et al. (284) is to use a
low cutoff value with troponin markers in serial samples
obtained on admission and at least $6 h after the onset of
symptoms. A low cutoff value uses the level of detectability
of the assays, and with that criterion, all patients at risk for
events during the first 30 days, even without additional
stress testing, are identified. The benefit of this strategy is
that it combines the early negative predictive value of rapidly
appearing markers with a high level of positive predictive
value. The disadvantage of this strategy is that minor
elevations of troponin are frequent in patients who have
hypertension, congestive heart failure and other clinical
syndromes that may cause minimal amounts of myocardial
damage.
The rapid availability of test results is essential. Most
laboratories acknowledge that a turnaround time of 30 to
60 min for these tests is standard. If the availability of results
takes substantially longer, point of care testing should be
considered (287). At present, the devices available are not as
accurate or as easy to use and interpret as they will likely
become; they are also several fold more costly, and regula-
tory issues add to the difficulty of their use. Nonetheless,
their use is advocated if laboratory turnaround times are
inadequate for the needs of the patients. It is clear that
strategies will need to be developed to accommodate local
needs. No matter what strategy is employed initially, it is
likely that in the long term, it will evolve into one predicated
on troponin markers.
Predictive instruments. The major reasons for develop-
ment of these decision aids are to standardize care and
improve efficiency. Physicians, in general, tend to be risk
adverse by nature, overestimate the probability of compli-
cations and have a low threshold for admitting low risk
patients (288). Accurate estimates of patients’ probabilities
for complications might support physicians in their transfer
of low risk patients to be treated at non-CCU facilities or at
home. It has been shown, in patients presenting with chest
pain, that ECG and other clinical data predict risk of acute
MI (289), and these factors also predict which patients will
have complications (267). On the basis of clinical features,
patients can be stratified into four groups, with the risk of
major complications in the first 72 h ranging from 0.7% to
20% (267). These data can also be used to stratify patients
according to their risk of long-term complications (248).
Decision aids have been adapted and incorporated into
computerized ECG reports to help clinicians in the triage
process (234,290).
Although studies continue to show that algorithms based
on multivariate statistical techniques have the potential to
improve medical decision-making (291), prospective trials
have consistently shown minimal or no impact of attempts
to use these algorithms in practice (292–294). Some data
indicate that physicians do not use these algorithms because
they are too busy or do not perceive their value (292), or
because they are concerned about the medicolegal and
clinical consequences of inappropriate discharges of patients
(295,296). An important current focus of research is to
integrate decision aids into routine data acquisition, such as
through predictive instruments (234) or critical pathways
(297).
Guidelines and critical pathways. Standards of care for
the initial evaluation of patients with chest pain have been
developed by several organizations, including the American
College of Emergency Physicians (ACEP) (298). These
guidelines stress that the decision to admit the patient must
be primarily based on clinical judgment and do not make
recommendations about levels of care (CCU versus inter-
mediate care of CPC) for different patient subsets. The
ACEP statement provides “rules” and “guidelines” about the
data that should be obtained, and recorded, as part of the
evaluation, as well as the actions that should follow from
certain findings. “Rules” are considered actions that reflect
principles of good practice in most situations. “Guidelines”
in the ACEP document are actions that should be consid-
ered; there is no implication that failure to follow a
“guideline” constitutes improper care. These guidelines also
emphasize the need for a functional design of the program,
appropriate staffing, quality assurance and outreach, in
addition to the ability to diagnose and initiate therapy in
patients with acute MI and unstable angina and to evaluate
those low risk patients with chest pain.
The National Heart Attack Alert Program (NHAAP)
has issued guidelines for specific functions related to evalu-
ation and treatment of patients with chest pain aimed at
improving the speed with which patients with acute MI are
identified and treated (265). Guidelines for the care of acute
MI and unstable angina are available to direct care for
patients with clear evidence of those syndromes
(266,272,299).
Guidelines from the Agency for Health Care Policy and
Research (AHCPR) for unstable angina indicate that not all
patients with this syndrome require admission, but recom-
mend ECG monitoring patients with unstable angina
during their evaluation; those with ongoing rest pain should
be placed in bed rest during the initial phase of stabilization
(264). The ACEP policy statement indicates that patients
who are discharged should be provided a referral for
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follow-up care, as well as instructions regarding the treat-
ment and circumstances that require a return to the ED
(298).
Institutional guidelines to increase efficiency have gener-
ally emphasized two strategies: 1) triage of low risk patients
to non-CCU–monitored facilities such as intermediate care
units or CPCs; and 2) shortened lengths of stay in the CCU
and hospital. Recommendations regarding the minimal
length of stay in a monitored bed for a patient who has no
further symptoms have been decreasing over the last two
decades from 24 h (300) to 12 h (301), to even shorter
periods if exercise testing or other risk stratification tech-
nologies are available (254,297).
Several studies have shown inconsistent application and
impact of guidelines. In one study, there was no effect on
admission rates, triage decisions or length of stay (293). In
another, a 26% reduction in length of stay resulted in use of
the guideline (302).
One strategy for optimizing and streamlining care is
through critical pathways (297,303). These predefined pro-
tocols outline and manage the crucial steps in defining a
clinical problem and treating that patient and aim to
improve quality of patient care, reduce variability and
enhance efficiency. Data are collected to define the rate-
limiting steps for each patient group and to provide feed-
back to health care providers and managers regarding the
care rendered.
There are at least two important differences between a
critical pathway and more traditional guidelines: 1) critical
pathways define time goals for the performance of key tasks;
2) critical pathways should be used to collect information on
rates at which these tasks are performed within the target
period.
Data on the impact of critical pathways on efficiency and
patient outcomes are not yet available. Such data are likely
to have limited generalizability, because the effectiveness of
a pathway depends heavily on the capacities of the institu-
tion in which it is implemented and whether data are fed
back to clinicians as part of a quality-improvement process.
Furthermore, pathways evolve quickly with the adoption of
new technologies such as cardiac markers of injury.
Exercise testing. Recent studies have confirmed the safety,
accuracy and utility of early treadmill exercise testing in low
risk patients presenting to the ED with chest pain. These
data stem primarily from investigations of patients with
negative evaluations in accelerated diagnostic protocols (6 to
12 h of monitoring, negative serial cardiac biomarkers) who
then undergo predischarge exercise testing. In this context,
the test is used to determine the need for further inpatient
evaluation (positive test) or suitability for discharge with
follow-up (negative test). Accelerated diagnostic protocols,
including exercise testing as a key element, have been
associated with reduced hospital stay and lower costs. There
have been no adverse effects of exercise testing in this
setting, and a negative test has accurately identified low
prognostic risk (i.e., patients with negative evaluations on
accelerated protocols have had the same posthospital course
as those with negative findings with traditional, longer
hospital stays) (254,255). Exercise treadmill testing has been
adequate for evaluation after a negative accelerated protocol.
There are no data indicating that stress imaging tests add to
predictive accuracy in this group.
One group has employed “immediate” exercise testing of
low risk patients in the ED without previous evaluation by
serial cardiac biomarkers (304,305). These patients were
clinically stable and had normal or near normal ECGs and
a negative screening evaluation (physical examination, chest
radiograph). This method has been safe and effective, with
no adverse effects of exercise testing in .1,000 patients
(306), and has been used to identify patients who could be
discharged directly from the ED and those who required
admission. However, it has been associated with a low
(,1%) rate of inadvertent testing of patients with inappar-
ent non–Q wave MI (306). This approach requires further
study.
Echocardiography. Left ventricular wall motion abnor-
malities in a patient with acute chest pain should be
considered suggestive of ischemia (307). However, echocar-
diography cannot distinguish new abnormalities of wall
motion or systolic wall thickening (due to either reversible
ischemia or acute infarction) from those that are old
(previous infarction), and it may detect abnormalities that
are unrelated to ischemia in patients with conduction
abnormalities such as paced rhythms and bundle branch
blocks, thus limiting its specificity. In addition, with mini-
mal or nontransmural myocardial involvement, even with
acute MI, wall motion abnormalities may not be detected by
early echocardiography (308).
In general, the sensitivity and specificity of the echocar-
diogram for detecting acute ischemia as the etiology of chest
pain symptoms are best when it is used during or soon after
an episode of pain. Small studies in highly selected groups
without a previous infarction or other cardiac abnormalities
have shown sensitivities and specificities of 86% to 92% and
53% to 90%, respectively, in this setting (207). In one
unselected group with chest pain, 94% of patients had
technically adequate images for assessment of ischemia, and
even in these patients, the sensitivity and specificity were
only 93% and 57%, respectively (309). However, echocar-
diography may provide information such as abnormalities of
global left ventricular function or wall motion suggestive of
previously unrecognized CAD. Localized wall motion ab-
normalities may also help identify the culprit artery in acute
ischemia.
To be most useful for diagnosis and early risk stratifica-
tion, the echocardiogram would need to be available imme-
diately in the ED, with highly trained personnel to obtain
and interpret the study (310,311). Ideally this service would
be immediately available 24 h a day, seven days a week.
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Technology to provide transtelephonic interpretation of
digital images is available (312).
Finally, study of the economics of incorporation of
echocardiography into routine evaluation of chest pain in
the ED, or of basing triage decisions on its results, has yet
to be done. In early 1997, the NHAAP Working Group on
“Evaluation of Technologies for Identifying Acute Cardiac
Ischemia in the ED” (207,233) concluded that even in
highly selected groups, the sensitivity of echocardiography
was not sufficient to warrant its use for triage and risk
stratification in the ED. There remains a lack of compara-
tive, prospective clinical trial information on the diagnostic
performance, clinical outcomes and costs of using early
echocardiography for risk stratification and triage decisions
in chest pain evaluation in the ED (313–315).
Stress echocardiography. Stress echocardiographic testing
may be useful for risk stratification of patients with negative
cardiac markers or normal rest echocardiographic data
before discharge. The incremental value of stress echocar-
diographic imaging over standard ECG stress testing re-
mains to be determined. This is particularly true in patients
with baseline normal ECGs and in other groups (e.g.,
women, young men) in whom false positive rates for ECG
stress testing are relatively high (316,317).
Conclusions. Given the technical limitations, resource re-
quirements and somewhat limited sensitivity and incremen-
tal value of echocardiography in the ED setting, this
modality should have further prospective study in compar-
ison with standard strategies before recommending its
widespread use in acute chest pain evaluation.
Myocardial perfusion imaging in patients presenting to
the ED with an ACS. Investigations from the late 1970s
documented the power of planar thallium-201 imaging to
predict outcomes in patients presenting with ACSs (318–
320). New technetium-99m–based radiopharmaceutical
agents for myocardial perfusion are better suited for early
use by allowing “uncoupling” of the injection from imaging
and providing concurrent evaluation of function (321–325).
For optimal value, it is preferred that early perfusion
imaging be provided daily on a 24 h basis. The principal
barriers to providing this service around the clock are cost
and timeliness of radiotracer availability. In patients with an
ACS, the optimal value of imaging requires injection during
or as soon as possible after symptoms start (326). This can
only be accomplished if radiotracer is available in the ED
and an in-house staff member is available to perform the
injection at all times.
Clearly, the availability of imaging capability in or next to
the ED is optimal. All imaging studies should be performed
as gated tomographic acquisitions (327). Image interpreta-
tion should be performed by physicians with expertise in
nuclear cardiology, using both static perfusion and gated
functional images, as well as a cine film of the rotating
acquisition to evaluate patient motion and artifact. In the
case of a negative early imaging study, an appropriate
follow-up evaluation is indicated.
Repeat presenters to the ED with negative findings or
indications for coronary angiography. Among the low
risk patients with chest pain who present to the ED, there
is a subgroup with a pattern of repeat visits with consistently
negative cardiac findings and unrevealing evaluations for
noncardiac etiologies of their symptoms (328). These pa-
tients account for a disproportionate number of ED visits
for chest pain among the entire group with negative
findings. In these patients, it is reasonable to consider
cardiac catheterization and coronary angiography to docu-
ment the absence of cardiac disease or to identify an
unsuspected cardiac condition. A normal evaluation may
significantly relieve the cardiac focus and anxiety of many
patients and thereby decrease the number of ED visits when
symptoms arise. Negative findings also provide essential
information to the physician for management decisions in
subsequent ED visits by these patients with chest pain. In
addition, the detection of unsuspected cardiac disease by
catheterization affords the potential for definitive manage-
ment.
SUMMARY
Safe, cost-effective management of patients presenting to
the ED with chest pain is a continuing challenge. The
traditional low threshold for admission of these patients, in
order not to miss a life-threatening cardiac condition, has
resulted in a ,30% incidence of coronary events in those
admitted for chest pain. This approach has been neither
medically optimal nor cost-effective. It is now recognized
that the high and low risk groups of patients presenting with
chest pain can be recognized on presentation, facilitating
urgent therapy for the former and more deliberate evalua-
tion of the latter. Chest pain programs have been developed
for systematic implementation of innovative approaches.
Most CPCs focus on the low risk group and utilize
accelerated diagnostic protocols, usually comprising 6 to
12 h of monitoring and serial cardiac biomarkers, which, if
negative, are followed by stress testing (exercise ECG or
noninvasive cardiac stress imaging). These methods have
been safe and accurate and appear to be cost-effective. Most
patients in the low risk group with negative evaluations have
a noncardiac source of the chest pain, but follow-up evalu-
ation for noncardiac etiologies has been inadequate and
could improve care of these patients.
RECOMMENDATIONS
1. Nontraumatic chest pain in adults presenting to the ED
should prompt evaluation for an ACS.
2. Evaluation of chest pain should follow a comprehen-
sive, systematic, protocol-driven approach with the
goals of identifying 1) myocardial necrosis; 2) ischemia
at rest; and 3) stress-induced ischemia.
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3. The goals of initial assessment of the patient with chest
pain are 1) to distinguish patients with an ACS or other
serious etiology; 2) to assess the level of risk of adverse
outcomes in patients with a suspected ACS or other
serious etiology; and 3) to initiate rapid treatment in
patients with serious conditions, according to current
published guidelines.
4. Patient evaluation in the ED should include documen-
tation of diagnostic tests and management in coordi-
nation with the patient’s primary care physician and,
when appropriate, with a cardiologist.
5. Patients with negative evaluations for ACS should have
further studies for noncardiac causes of chest pain.
6. Chest pain centers facilitate rapid, efficient manage-
ment of high risk patients with an ACS and identifi-
cation of lower risk patients who do not require hospital
admission, by application of accelerated diagnostic pro-
tocols.
7. Chest pain centers may have a dedicated environment
and the coordinated efforts of specialized personnel or
may utilize personnel and process (“virtual units”) to
attain the objectives of safe, accurate and cost-effective
management of patients presenting with chest pain.
8. Accelerated diagnostic protocols should include 6 to
12 h of observation, ECG monitoring, serial cardiac
biomarkers and, in patients with negative findings,
stress testing before discharge.
9. Expertise in the recognition of typical and atypical
presentations of ischemic chest discomfort is man-
datory for physicians managing patients with this
presentation.
10. An ECG should be obtained and interpreted within
10 min or less of presentation of the patient with chest
discomfort, and, when possible, it should be recorded in
the presence and absence of chest discomfort.
11. Right-sided ECG leads should be recorded in patients
with evidence of inferior or posterior MI.
12. Posterior ECG leads (V7 through V9) should be re-
corded in patients in whom posterior infarction is
suspected.
13. The role of continuous ST segment monitoring in the
ED has not been established.
14. The results of cardiac biomarker testing should be
available within 30 to 60 min in patients presenting
with a possible ACS.
15. Because of their superior sensitivity and specificity for
identifying myocardial injury, the cardiac troponins are
currently the biochemical markers of choice for this
purpose.
16. Guidelines and critical care pathways are useful in that
they emphasize a systematic program for the manage-
ment of patients presenting with chest discomfort and
provide a basis for quality assurance, but they do not
replace clinical judgment. These guidelines also empha-
size the need for a functional design of the program,
appropriate staffing, quality assurance and outreach.
17. Standard echocardiography cannot be recommended
for routine use in the ED evaluation of patients pre-
senting with chest discomfort because of technical
limitations, resource requirements and limited incre-
mental diagnostic value.
18. Early rest nuclear imaging for risk stratification of
patients presenting with a possible ACS can be effec-
tively employed in institutions with appropriate re-
sources and expertise and can be cost-effective if patient
volume is sufficient.
19. The majority of patients presenting with acute chest
discomfort who have negative cardiac findings have a
noncardiac etiology of their symptom, which may be
gastrointestinal, musculoskeletal, pulmonary or psycho-
logical. These patients require further evaluation to
provide a basis for appropriate management.
20. Coronary angiography should be considered in selected
patients with repeat presentations to the ED for chest
discomfort with negative cardiac evaluations and no
other identifiable source of symptoms.
Task Force 3: Special Aspects of
Research Conduct in the Emergency
Setting: Waiver of Informed Consent
Eugene R. Passamani, MD, FACC, Co-Chair, Myron L. Weisfeldt, MD, FACC, Co-Chair
In the U.S., nearly 1,000 people die each day after experi-
encing a sudden, out-of-hospital cardiac arrest. Although
standard-of-care resuscitation efforts are applied on behalf
of most of these patients, the mortality rate is nevertheless as
high as 99% in some urban areas. The American College of
Cardiology (ACC) strongly advocates a vigorous program of
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medical research directed at improving these very dismal
outcomes. Because these patients are deprived of their
autonomy by their sudden cardiac arrest, the ACC also
believes it is essential to maintain these patients’ rights as
human beings during the course of their enrollment and
treatment as research subjects. Although informed consent
is one of the usual means of providing for such protection,
it is usually impossible in such emergency situations where
no “informing” or “consenting” can occur because of sudden
death or critical illness. Because therapy is highly time
dependent, and even 2 or 3 min can dramatically reduce
survival, consent by family members or other surrogates is
equally difficult.
Because critically ill and dying patients who are unable to
give consent are often individuals for whom new advances
are likely to be life-saving, the Food and Drug Administra-
tion (FDA) and National Institutes of Health (NIH) have
recognized that conditions for the conduct of research in
these patients must be specified (329). The recently pro-
mulgated FDA regulations stipulate the conditions for
ethical research when the informed consent requirement is
waived. Examples of abuse of patients’ rights from the
recent past, most notably from the Department of Energy’s
radioactive materials studies, have underscored that such
oversight of the conduct of research is imperative (330).
Unfortunately, confusion and uncertainty about the
application of these regulations are significantly impairing
the national research community’s efforts to improve the
outcomes of these most severely ill Americans. Implemen-
tation at the local level of the new regulations for cardiac
arrest victims and other emergency patients (329) is cur-
rently vague and burdensome. The nation’s research
projects, and thus its efforts to improve the outcomes of
cardiac arrest, were stopped entirely between 1993 and
1996. During this period, no waiver of informed consent
was valid. Furthermore, since the end of the moratorium
and the adoption of these new regulations, new projects are
proceeding very slowly, at a rate of less than two studies per
year. The task of this working group was to address and
attempt to establish clearer rules. We will begin by exam-
ining some of the history that has led to efforts to protect
human subjects.
PRE-1993 INFORMED CONSENT REGULATIONS
Much of the debate and confusion over informed consent
begins with the first principle of the Nuremberg Code,
which states that “the voluntary consent of the human
subject is absolutely essential” (see the event timeline in
Table 1 for important dates surrounding informed consent)
(331). This document did not address the need for research
on subjects who could not, for any number of reasons, give
their own “voluntary consent” (332), but focused on uneth-
ical research conducted in Nazi Germany, which deprived
healthy individuals of their autonomy. Research on subjects
who cannot give informed consent requires other means to
ensure that the research is ethical and the patients’ rights are
protected. It is widely recognized that informed consent is
not always needed for research to be considered ethically
acceptable. The World Health Organization’s Declaration
of Helsinki recognized that incompetent patients could be
subjects of research if consent was obtained from a proxy,
and went further to say that consent could be waived
altogether “if the physician considers it essential not to
obtain informed consent, the specific reasons for the pro-
posal should be stated in the experimental protocol for
transmission to the independent committee” (332).
The research community in the U.S. recognized the need
for a waiver of consent to allow research on patients who
could not give consent. Two major government regulatory
agencies that dealt with research (Department of Health
and Human Services [DHHS] and FDA) developed differ-
ent but unfortunately inconsistent regulations on the criteria
for waiver of informed consent. Under the regulations
Table 1. Timeline of Events Surrounding Informed Consent
1932 U.S. Public Health Service begins the Tuskegee
Syphilis Study (333).
1946–1947 Nuremberg Tribunal: “the voluntary consent of the
human subject is absolutely essential.”
1964 Declaration of Helsinki (334): recognized that a
proxy decision-maker is ethical for subjects who
lack decision-making capacity.
1972 Tuskegee Syphilis Study terminates (333).
1979 National Commission for the Protection of
Human Subjects of Biomedical and Behavioral
Research: The Belmont Report (335):
articulated three principles for research—respect
for persons, beneficence and justice.
1992 Public outcry over testing without consent, as
performed by the Department of Energy on
subjects with ionizing radiation (330).
1993 “Dear Colleague” letter from OPRR at NIH warns
Institutional Review Board chairs that deferred
consent does not meet regulatory compliance for
waiver of consent (336).
1994 The FDA terminates an ongoing human CPR
study and sends marshals to the homes of
investigators to confiscate devices.
Rep. Ron Wyden, Chairman of the House
Subcommittee on Regulation, Business
Opportunities and Technology, holds a public
hearing on waiver of consent in the emergency
setting.
1995 FDA and NIH co-sponsor public meetings to
discuss issues of informed consent.
Initial draft of proposed new rules released in
September (337).
1996 Final new rules released in October for waiver of
consent criteria (337).
1997 President Clinton formally apologizes to the
Tuskegee study subjects.
CPR 5 cardiopulmonary resuscitation; OPRR 5 Office of Protection from Research
Risks.
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developed by DHHS, researchers could get a waiver of
consent if four criteria were met (Table 2). However, a
major problem developed because of the requirement that
the research involve no more than minimal risk. This “no
more than minimal risk” clause seemed to preclude almost
all emergency research, because these situations were likely
to involve more than minimal risk. However, some emer-
gency research was carried out under this regulation when
investigators interpreted minimal risk to mean the differen-
tial risk in outcome for the experimental treatment as
compared with standard treatment, not the risk compared
with the risks of daily life. In addition, “deferred consent”
was used in some studies. Under deferred consent, a patient
was initially entered into the study, and then later, when the
patient became competent or a proxy was identified, consent
(or no consent) to remain in the study after initiation of
therapy was obtained. Different organizations interpreted
these practices and regulations differently.
During this period, the FDA regulations allowed for a
waiver of informed consent for nonresearch “compassionate
use” purposes, only using different criteria (Table 3). A
serious difficulty with these criteria was the use of the phase
“necessary” to save the life of a patient, as this seemed to
eliminate the use of control groups. It was impossible to
claim that participation in the placebo arm of a trial was
“necessary” to save a life. These ambiguities created multiple
problems for researchers, Institutional Review Boards
(IRBs) and regulatory agencies. Concerns were being ex-
pressed that studies were done “outside of the rules.” Some
IRBs would approve a study, whereas other IRBs would
reject the same study. Some investigators and companies
would not even consider initiating the efforts and resources
to advance a proposal owing to the confusing situation. To
make matters even worse, many studies required both NIH
and FDA oversight and had to meet both sets of criteria.
THE 1993 “MORATORIUM”
ON EMERGENCY RESEARCH
The issue came to a crisis in 1993, when the Director of the
Office of Protection from Research Risks (OPRR) at the
NIH warned IRB chairs in a “Dear Colleague” letter that
using deferred consent was not in compliance with DHHS
rules on waiver of consent and that any type of consent
mechanism that did not involve prospective waiver of
consent was not in compliance (336). The effect of this letter
was to place a moratorium on all human resuscitation
research in the U.S. The fear of regulatory action against the
research community became real when the FDA sent armed
U.S. marshals to the homes of CPR investigators to
confiscate suction-cup devices when the FDA terminated a
study in progress because of concerns about informed
consent. An IRB had approved this trial, and no apparent
adverse effects had been noted at the time of the suspension.
The FDA also terminated a study on head trauma owing to
informed consent issues and only allowed enrollment of
patients for whom informed consent could be obtained
prospectively in an antioxidant study.
Multiple efforts began to develop new rules for waived
consent that would permit emergency care research on
impaired subjects. A national consortium of emergency care
researchers was created. Rep. Wyden, Chairman of the
House Subcommittee on Regulation, Business Opportuni-
ties and Technology, held a public hearing on waiver of
informed consent in the emergency setting. A new set of
rules was distributed in September 1995, additional hear-
ings took place and a final rule was adopted in October 1996
(337). The 1996 final FDA rule allowed waiver of informed
consent under a limited set of criteria (Table 4, abridged
version).
AFTER THE 1996 FINAL RULE (21 CFR 50.24)
With the final rules for waiver of informed consent pub-
lished in 1996, the way for a waiver of informed consent on
new studies seemed to be clear. The FDA hosted a
“National Conference on Implementation of the Waiver of
Informed Consent in Emergency Situations” on September
29–30, 1997. The new rule and issues of implementation
were described, and public commentary was solicited (338).
There was substantial controversy over the new rules. Since
then, most written statements in the published data have
Table 2. Pre-1993 DHHS Policy on Waiver of
Informed Consent
The Department of Health and Human Services (i.e., NIH)
allowed a waiver of consent only if all of the following were
true:
1. The research involves no more than minimal risk to the
subjects.
2. The waiver will not adversely affect the rights and welfare of
the subjects.
3. The research could not practically be carried out without the
waiver.
4. Subjects are provided with additional pertinent information
after participation, as appropriate.
Table 3. Pre-1993 Food and Drug Administration Regulation
on Waiver of Informed Consent
The FDA permitted a waiver of consent for nonresearch
“compassionate use” if all four of the following conditions
were met:
1. The human subject is confronted with a life-threatening
condition necessitating the use of a device or drug.
2. Informed consent cannot be obtained from the subject
because of an inability to communicate with or obtain legally
effective consent from the subject.
3. Time is not sufficient to obtain consent from the subject’s
legal representative.
4. There is no alternative method of approved or generally
recognized therapy available that provides an equal or greater
likelihood of saving the life of the subject.
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been supportive of the final rules; some strong opposition
was also voiced (337,339). Some critics suggested that the
new rules were regressive and in violation of the Nuremberg
Code. They also questioned the claim that the patient may
benefit from experimental therapy (339).
Although these rules allow for waiver of informed con-
sent under very limited circumstances, they also created a
new set of obstacles for researchers: they require a vaguely
defined community consultation and a public disclosure
program (336,339–341). Santora et al. (340) described the
stepwise process followed at the Allegheny University of the
Health Sciences to comply with the requirement for public
disclosure. This procedure required 80 person-hours to
complete and included four public meetings, newspaper
notices, radio public service announcements and a 24 h
telephone hotline. Another report of efforts to comply with
the new rules revealed that the institution had to increase
community representation on their IRB, fund newspaper
notices, create a call-in telephone line, hold public forums,
make presentations to the Department of Medicine and
Medical Boards, create a videotape presentation, provide
literature in the physician lounge, put up large posters, put
brochures in patient rooms and have charge nurses notify
patients (342). A total of 25 people from a community of
nearly 1.5 million people attended the public forum. The
direct costs for the public disclosure was $5,600. A total of
four patients were enrolled in the study over four months.
The authors reported confusion as to what was sufficient for
a broad community consultation/public disclosure criterion.
If the “public disclosure” dilemmas were not enough for
researchers, a survey of what patients actually think about
the 1996 FDA rule (21 CFR 50.24) suggests an even rockier
road ahead for the rules. Smithline and Gerstle (343)
surveyed a convenient sample of 212 emergency patients.
Only half of the patients were in agreement with a waiver of
consent for serious illness, using the new rules. This
discordance between patient desires and regulatory require-
ments will likely lead to future conflicts for the research
community.
In addition, the following new procedural protections are
required: 1) consultation with the community in which the
research will occur; 2) informing the subject, if feasible,
representative or family member at the earliest point,
including in the event of death; 3) public disclosure of the
study results when completed; 4) use of an independent data
safety board; and 5) approval of the study by the FDA.
STATEMENT OF THE PROBLEM
Traditional informed consent for human research is impos-
sible or difficult in a number of common medical conditions.
The Emergency Department or the prehospital care envi-
ronment is often the site where such emergencies occur,
even if one limits the focus to cardiovascular conditions.
Informed consent is usually impossible to obtain during
cardiac arrest, acute congestive heart failure, sepsis or
hemorrhage, stroke syndrome, drug overdose with hemody-
namic compromise, severe hypoxia related to acute or
chronic pulmonary disease, severe metabolic acidosis and
alteration in sodium or hydration with altered mental status.
There are also a number of conditions for which “consent”
can be obtained from the patient, even though it is likely
that the detailed and prolonged explanation may not be fully
understood by the patient. Such circumstances might in-
clude circulatory catastrophes requiring an immediate inter-
vention (e.g., ruptured ventricle, valve or aorta), massive
hemorrhage, pulmonary embolism with severe hypoxemia,
congestive failure with shock, myocardial infarction with
severe pain or dyspnea, life-threatening arrhythmia with
hypotension or hypertensive crisis. A “standard of reason-
ableness” with regard to the adequacy of informed consent is
often not met.
Research requiring informed consent or a waiver in such
settings would include not only new therapeutic strategies
but also studies involving a protocol approach to medical
effectiveness, or implementation of care plans with a re-
search focus that involves more than minimal risk. Minimal
risk is usually limited to drawing a very small amount of
venous blood, blood testing and data gathering.
ISSUES IN OBTAINING INFORMED
CONSENT IN EMERGENCY SITUATIONS
The FDA requires that the investigators attempt to obtain
informed consent from the patient “under all reasonable
conditions” (337). A waiver of informed consent is only
considered where informed consent is not possible.
Intense efforts to obtain informed consent before circum-
stances such as a cardiac arrest raise a number of issues
worthy of consideration. These issues include whether
informed consent from an individual who is not yet a
candidate for a study and is not yet experiencing an
emergency is a valid consent. A patient who is not yet a
candidate may be more concerned about avoiding candidacy
than receiving treatment should a catastrophe occur. Would
an individual refuse consent in the belief that consent would
Table 4. Abridged Highlights of the 1996 Food and Drug
Administration Rule (21 CFR 50.24)
The central themes of the final 1996 rule were:
1. The patient has a life-threatening situation.
2. Available therapies are unproven or unsatisfactory.
3. Direct consent from the patient is not feasible because of the
patient’s condition and because therapies must be started
before an authorized surrogate representative can be
contacted.
4. The research cannot be reasonably conducted otherwise.
5. The risks and benefits of the experimental protocol are
considered reasonable in light of the patient’s condition and
what is known about the other available therapies.
6. Participation in the research holds out the prospect of direct
benefit to the subject.
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lead to less effort by the provider to avoid candidacy?
Alternatively, would a subject agree to participate in a study
if he or she believes their candidacy is unlikely, to please a
physician or investigator and to gain more attention?
A second issue raised by an intense effort to obtain
informed consent before an emergency situation is the
number of informed consents needed to gain one patient
candidate. What is the psychological impact on a patient of
the approach for consent in the event of an adverse outcome
that has only a 1 in 500 chance of occurring? If large
numbers of patients are to be consented, how detailed does
the consent need to be?
Finally, the ability of a patient to understand detailed
information during an emergency may be severely compro-
mised. Is there a role for an abbreviated consent procedure
with a simple level of understanding, rather than a detailed
form, which would be appropriate in the nonemergency
setting? We believe it is not reasonable to attempt to obtain
informed consent before medical circumstances that may
come under study for many patients with cardiac disease.
JUSTIFIABLE RESEARCH AND CLINICAL EQUIPOISE
Imperatives during biomedical research include an improved
understanding of illness and, through this knowledge, better
diagnosis, treatment and prevention. However elegant and
conclusive preclinical research on a new device, drug or
concept may be, diagnostic and therapeutic strategies must
be tested in patients before widespread use.
Publication of a clinical trial testing streptomycin as a
treatment for tuberculosis nearly 50 years ago led to wide-
spread use of clinical trial methodology in testing new drugs
and surgical techniques (344,345). The demand for properly
conducted, randomized, controlled animal experiments and
clinical trials before general use has protected patients from
useless or toxic therapy, although the ethical correctness of
clinical trials has been debated periodically (346,347). The
requirement for clinical equipoise and informed consent
protects patients from exposure to poorly designed and
dangerous clinical trials.
As noted earlier, clinical equipoise is the state in which
the medical community, after careful review of the totality
of evidence, is convinced that none of the therapies tested in
a randomized trial are clearly established to be more effective
(348). Trial design may compare a therapy with placebo or
the best-established therapy (i.e., standard of care). Periodic
review of the data developed during the course of a trial by
a duly constituted Data and Safety Monitoring Board
(DSMB) assures that clinical equipoise remains for the
entire research period. If, at any time, one therapy is clearly
shown to be superior to another, the DSMB has the duty to
terminate the study.
A critical part of the Nuremberg Code (349) and the
Declaration of Helsinki (350) is the requirement to inform
all subjects involved in medical experimentation before entry
into a study. They must know the goals of the experiment
and the potential risks, benefits and alternatives. They have
the right to withdraw from the study at any time. This is
particularly true of vulnerable populations, such as children,
those who are mentally impaired or prisoners.
Respect for a subject’s autonomy is the underlying ethical
principle of informed consent. An important aspect of
informed consent is the capacity to understand the goals of
the research effort and the attendant risks, benefits and
alternatives. Patients brought to medical attention in the
midst of a severe illness, particularly an illness that disables
the central nervous system, may not be able to give informed
consent and can be thought of as having a disability. This is
particularly true for patients who have a cardiac arrest.
Relatives or friends who might be able to communicate the
patient’s wishes are often not available in a time frame that
would permit entry into a trial using time-sensitive treat-
ments.
Such “disabled” men and women are unable to participate
as subjects in a randomized, controlled study using tradi-
tional safeguards. The aggregate effect of intellectually
disabled patients not getting into clinical trials has resulted
in little or no progress in testing new, potentially effective
treatments for such severe illnesses. These patients are
desperately ill; some never recover; and many die. Holding
informed consent in abeyance requires strict documentation
of initial and continuing equipoise and may need the
involvement of community leaders, including those without
ties to medicine or research.
ETHICAL PERSPECTIVE ON
WAIVING INFORMED CONSENT
Clinical research places individuals at risk to develop gen-
eralizable knowledge that can be used to improve societal
health and well-being. By placing some at risk for the good
of others, clinical research has the potential to exploit its
subjects. To justify the risks of clinical research and ensure
that subjects are not exploited, seven ethical requirements
must be met (Table 5).
First, subjects should be placed at risk only when the
research concerns a socially, scientifically or clinically im-
portant question—one that can improve overall health and
well-being. In this sense, “me too” studies are not valuable
and not ethically justifiable. Next, the research plan must be
valid scientifically; it must offer a good chance of answering
the question(s) posed. In this sense, only good clinical
research can be justified ethically. Studies that are under-
powered or not generalizable or that use biased statistical
techniques are not ethical. Third, subjects must be selected
in a fair manner. Fair subject selection requires that risky
research not be limited to the underprivileged, nor that
potentially beneficial research be extended to the privileged.
Rather, inclusion and exclusion criteria and subject recruit-
ment strategies must be based on scientific criteria relevant
to the information sought. Fourth, research should offer the
most favorable risk-benefit ratio possible. To meet this
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requirement, the risks of research must be minimized and
the potential social and individual benefits maximized.
When the potential benefits to individual subjects are
proportionate or outweigh the potential risks they face,
clinical research is ethical. When the potential benefits to
individual subjects do not outweigh the risks to them, as in
phase I research, then clinical research is justified only when
its potential social benefits outweigh the “excess” risks to
individual subjects. Although the first comparison of bene-
fits and risks to the same individual is fairly clear and
performed routinely, the comparison of social benefits to
individual risks is more complex and lacks a clear method-
ology. Fifth, because investigators may have conflicts of
interest between safeguarding subjects and completing their
research, and because research must be accountable publicly,
research studies should be reviewed by an independent body
with the expertise to evaluate the study and the power to
approve, revise or even stop it. Sixth, when possible,
research subjects should provide informed consent before
research enrollment, and continuing consent periodically
throughout their participation. Finally, ethical clinical re-
search requires that investigators respect potential and
enrolled subjects. This includes respecting subjects’ privacy,
informing them of what is learned from the research and
carefully monitoring their welfare, even if it means with-
drawing them from the research if the harms and side effects
become too great.
Valid informed consent requires the completion of four
separate steps. The first three steps constitute the informed
portion of the requirement. Subjects must be informed
concerning the research study that they are being asked to
participate in, including its objective, procedures, risks,
potential benefits and alternatives. Second, they must un-
derstand this information. Third, physicians and researchers
must inform subjects about their medical condition, includ-
ing their diagnosis and prognosis; subjects must also under-
stand this information. Finally, in the consent portion,
subjects must make a voluntary decision whether to enroll
on the basis of this information, and in light of their own
preferences and values.
Why is informed consent important ethically and what
are the special ethical concerns raised by conducting human
subject research without it? Obtaining informed consent
before research enrollment helps to respect subjects’ auton-
omy by allowing them to decide whether or not to enroll. In
addition, because individuals are typically in the best posi-
tion to judge their own interests and values, requiring
informed consent increases the chances that individuals will
be enrolled in research only when it is consistent with their
personal preferences and values. Therefore, conducting
Table 5. Seven Requirements That Make a Research Trial Ethical
Requirement Explanation Justifying Ethical Values
Social or scientific value Evaluating a treatment, intervention or theory that will
improve health and well-being or increase
knowledge.
Scarce resources and avoidance of
exploitation
Scientific validity Stating a clear hypothesis, using accepted scientific
principles and methods, including statistical
techniques, to produce reliable and valid data.
Scarce resources and avoidance of
exploitation
Fair subject selection Selecting subjects so that stigmatized and vulnerable
individuals are not selected for risky research, while
favored classes are offered potentially beneficial
research.
Distributive justice
Favorable risk-benefit ratio Minimization of potential risks and harms with
maximization of potential benefits so that the risks
to the subject are proportionate to the benefits to
the subject and society.
Nonmaleficent, beneficence,
nonexploitation
Independent review Review of the design of the research trial, its proposed
subject population and risk-benefit ratio by an
individual who is unaffiliated with the research.
Minimizing potential conflicts of interest,
public accountability
Informed consent Provision of information to potential subjects about
the purpose of the research, its potential risks,
benefits and alternatives, so that the individual
understands this information and can make a
voluntary, uncoerced decision about participation in
the study.
Respect for subject autonomy
Respect for potential and
enrolled subjects
Respect for subjects by 1) permitting withdrawal from
the research; 2) protecting privacy through
confidentiality; 3) informing of newly discovered
risks or benefits; and 4) informing about the results
of clinical research.
Respect for subject autonomy and welfare
867JACC Vol. 35, No. 4, 2000 Passamani and Weisfeldt
March 15, 2000:825–80 Task Force 3: Special Aspects of Research Conduct in the Emergency Setting
research without informed consent raises two ethical con-
cerns: 1) investigators may fail to respect subjects’ auton-
omy; and 2) individuals may be enrolled in research that
conflicts with their preferences and values.
The emergency setting frequently does not offer sufficient
time to inform potential subjects of the nature of the
research or obtain their consent. In addition, the ailments
on which emergency research focuses—such as stroke,
myocardial infarction and acute brain injury—frequently
render individuals incapable of understanding during the
time treatment must be initiated. For these reasons, research
in the emergency setting often cannot meet the four
conditions for informed consent. As a result, the ethical
conduct of emergency research often depends on the pos-
sibility of waiving the requirement for informed consent.
Arguments in support of waiving informed consent in
limited cases focus on three claims. First, because many
emergency treatments are unproven or unsatisfactory, it is
important to identify more effective alternatives. Second, in
a related way, because many emergency interventions have
dismal outcomes, subjects may benefit—or not be harmed,
as compared with conventional care—from enrolling in
emergency research.
Finally, by using other safeguards, it is possible to ensure
that the interests of individuals who are enrolled in emer-
gency research without their consent are protected and that
they will not be exposed to excessively risky procedures.
The FDA regulations allow for a waiver of informed
consent before enrollment in emergency research under the
13 conditions outlined in Table 6. The study and waiver are
approved by the relevant IRB.
To what extent do these 13 conditions ensure that
emergency research conducted without informed consent
meets the seven requirements on ethical research? In addi-
tion, do these conditions satisfactorily address the special
ethical concerns raised by waiving informed consent?
The FDA regulations address the requirement for social,
scientific or clinical value by stipulating that subjects must
have a life-threatening condition; available treatments must
be unproven or unsatisfactory; and the collection of valid
scientific evidence must be necessary to determine the safety
and effectiveness of particular interventions (condition 2).
Presumably, when these conditions are met, the develop-
ment of alternative treatments has social value. However,
two problems arise. First, there is some vagueness in this
condition: how unsatisfactory must the treatments be to
justify research without informed consent? Is a 10% success
rate of the conventional intervention or a 25% success rate
sufficiently bad? Is a 50% survival rate with 30% permanent
brain injury sufficiently bad? The difficulty here is that the
regulations do not require a minimal level of value to justify
research without informed consent, nor would it be reason-
able to provide such arbitrary limits.
The FDA regulations address the requirement that clin-
ical protocols present the most favorable risk-benefit ratio
possible by stipulating that participation must hold out the
prospect of direct benefit to the subjects (condition 4) and
risks must be reasonable (condition 5). These conditions
ensure that subjects of emergency research do not face
excessive risks or participate in research with no potential
for benefit. However, these conditions do not fully address
the special ethical concern that a waiver of informed consent
Table 6. How Well Do Food and Drug Administration Provisions Satisfy Requirements for Ethical Research and Address Ethical
Concerns of Waiving Consent?
Provision Ethical Requirement or Concern Addressed
1. IRB approval Independent review
2. Life-threatening situation without satisfactory treatment Value
3. Informed consent not feasible Informed consent when possible
4. Prospect of direct benefit Most favorable risk-benefit ratio
Potential for unwanted research enrollment
5. Risks are reasonable Most favorable risk-benefit ratio
Potential for unwanted research enrollment
6. Impracticable to conduct research without waiver Informed consent when possible
7. Commitment to contact legally authorized representative Respect for enrolled subjects
8. Community consultation Independent review
Potential for especially risky research with waiver
9. Public disclosure of research plan Independent review
Potential for especially risky research with waiver
10. Public disclosure of research results Respect for enrolled subjects
11. Independent oversight board Independent review
Respect for enrolled subjects
12. Investigator informs subject, representative or family
member at earliest possible point
Respect for enrolled subjects
Ethical concern that waiver of informed consent will diminish
respect for subject autonomy
13. Investigator provides information about subjects who
die before notification
Respect for enrolled subjects
IRB 5 Institutional Review Board.
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may lead to individuals being enrolled in research that
conflicts with their preferences. Even if most individuals are
willing to participate in research that offers the most
favorable risk-benefit ratio, these conditions do not ensure
that emergency research in which consent is waived meets
this condition—a reasonable level of risk can outweigh an
unspecified potential for direct benefit.
To address this concern, the American Medical Associ-
ation guidelines (351), as well as the preamble to the FDA
regulations, argue that informed consent should not be
waived unless there is clinical equipoise (337). When it
does, individuals enrolled in emergency research without
their consent will not face a less favorable risk-benefit ratio
than individuals who receive standard of care; hence, there
is good reason to believe that such enrollment will not
conflict with the individual’s preferences. However, the
FDA’s stated conditions—that subjects must have a life-
threatening condition, available treatments must be un-
proven or unsatisfactory and collection of valid scientific
evidence must be necessary to determine the safety and
effectiveness of particular interventions—are not equivalent
to clinical equipoise. These conditions do not compare the
experimental treatment being studied directly with any
existing standard treatments, which are necessary to assess
equipoise. As a result, they do not ensure that clinical
equipoise exists.
Although it is very difficult to fully address the possibility
of unwanted research enrollment, the regulations would
need to address the possibility that some individuals may
have idiosyncratic preferences and values that get left out of
the assessment of equipoise. For example, the risks from a
treatment arm that involved a blood transfusion might be
deemed low by most individuals in our society, but would be
considered extremely risky to many Jehovah Witnesses.
The FDA conditions provide for significant independent
review in addition to the usual IRB review (condition 1).
Investigators who request a waiver must establish an inde-
pendent monitoring board (condition 11) and consult with
community representatives (condition 8). In addition, they
must disclose their research plan and results (conditions 9
and 10) publicly. Such a comprehensive level of independent
review ensures that research without informed consent is
not likely to expose subjects to excessive risks. Indeed,
combining the conditions for a favorable risk-benefit ratio
with this added level of independent review obviates an
important concern that informed consent is meant to
address—namely, that research could be so risky as to pose
a threat to individuals and conflict with subjects’ prefer-
ences.
The FDA regulations require that investigators obtain
informed consent when possible, by stipulating that requests
for a waiver may be approved only when the research could
not be carried out practicably without the waiver (condition
6) and obtaining consent is not feasible (condition 3). In
addition, they ensure that proxy consent is not possible, by
requiring that investigators attempt to contact a legally
authorized representative for each subject (condition 7).
The regulations define consent as not being “feasible” in
terms of three conditions: 1) subjects are not able to give
consent owing to their medical condition; 2) the interven-
tion being tested must be administered before it is feasible
to get proxy consent; and 3) it is not possible to identify
subjects prospectively. Taken together, these conditions go
a long way toward ensuring that research without informed
consent is done only when necessary.
The FDA regulations address the need to respect poten-
tial and enrolled subjects by requiring investigators to
attempt to contact a legally authorized representative or
family member and that subjects be notified at the earliest
time possible (condition 12). This last requirement also
helps to address the special ethical concern that research
without informed consent fails to respect individuals’ au-
tonomy. Finally, for subjects who die before notification, the
regulations stipulate that information be provided to the
legally authorized representative or family member when
feasible (condition 13).
Overall, the FDA regulations go a long way toward
ensuring that the ethical requirements for clinical research
are fulfilled in emergency research where subject consent is
not possible. In particular, attention to the risk-benefit ratio
and comprehensive independent review beyond IRB review
ensures that subjects unable to consent will not be enrolled
in excessively risky research. Although there remain some
areas of disagreement, mostly about how difficult it should
be to obtain consent before the waiver can be invoked, the
conditions do ensure that emergency research with the
waiver will fulfill the other ethical requirements.
PROBLEMS RELATED TO
THE FDA/DHHS REGULATIONS
ALLOWING A WAIVER OF INFORMED CONSENT
Although the FDA/DHHS regulations have been assessed
to be ethical in terms of their requirements for special
patient protections, there still exist a number of ambiguities
that make the application difficult, hence making them
susceptible to misinterpretation and misapplication. A few
specific examples of problems related to the interpretation of
the regulations follow.
There must be disclosure to the community in which the
clinical investigation is to be conducted. The question is,
what constitutes adequate community notification? A wide
variety of approaches to this difficult problem have been
used, including newspaper advertisements, interviews with
media, open discussions, meetings with concerned citizen
groups, and many of these approaches involve considerable
cost and considerable time and delay. What is adequate?
The FDA provisions also require community consulta-
tion. What constitutes reasonable consultation? What if
there is limited objection to the study as a whole? It is
important to point out that the FDA provisions do not
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require public input into the study protocol. Instead, it
requires community consultation, but what occurs during
community consultation cannot by itself block the conduct
of the study. Community consultation might raise issues
that the IRB has not considered. It is up to the IRB, in
conjunction with the investigator, to determine whether
these community concerns are sufficient to warrant a change
in the protocol. There is absolutely no requirement in the
FDA regulations indicating that a community can have
direct input into changing the study. Instead, a community’s
responsibility is to raise concerns that should then be
considered by the IRB and the investigator.
Finally, these regulations governing waiver of informed
consent have particularly imposing aspects for IRBs and
institutional leaders. The regulations require provision of
the information to the patient as soon as possible. When
alert, the patient must be informed that he or she was
included in a research study and provided the option for
discontinuation of involvement. If the person does not
resume consciousness or succumbs to the illness, the next of
kin or immediate family member must be informed imme-
diately of the patient’s inclusion in a research study without
informed consent. In the latter situation, there is great
concern of litigation. It is interesting to note that the same
provisions were developed when deferred consent was ap-
plied.
The risk of litigation would likely be reduced if there was
very detailed documentation of appropriate adherence to the
guidelines and regulations. Because the regulations for
community notification and public input are currently ex-
tremely broad, it will be difficult to legally defend the
measures taken as adequate.
PROPOSAL FOR A NATIONAL
CONSENSUS ADVISORY BODY
The 31st Bethesda Conference on Emergency Cardiac Care
proposes a national advisory consensus body (committee).
There is precedent for the creation of a governmental
advisory body related to an area of research in which there
is significant public concern. The Recombinant Advisory
Committee (RAC) was established in 1974 in response to
public concerns regarding the safety of manipulation of
genetic material through the use of recombinant deoxyribo-
nucleic acid (DNA) techniques. This body was established
as an advisory to the Director of the NIH and focused on
concerns “that recombinant DNA technology would be
associated with possible hazards relating to new types of
organisms, some potentially pathogenic, that could be
introduced into the environment without effective controls.”
The RAC developed a set of guidelines for the use of
recombinant DNA materials that have been revised repeat-
edly since 1976. The guidelines include a comprehensive
description of facilities and practices intended to prevent
unintended release or exposure to genetically modified
organisms. Compliance with these guidelines was made
mandatory at institutions receiving NIH funds for research
involving recombinant DNA. Many companies complied
with the NIH guidelines voluntarily and had representatives
that were part of the RAC draft meetings and deliberations.
The Director of the NIH was required to seek the advice of
the RAC before taking specific actions, including changing
containment levels for types of experiments that are speci-
fied in the NIH guideline; assigning containment levels for
types of experiments that are not explicitly considered in the
NIH guidelines; certifying new “vector” systems; promul-
gating and amending a list of classes of recombinant DNA
molecules to be exempt from NIH guidelines; adopting
other changes in NIH guidelines; and interpreting and
determining containment levels on the request of other
regulatory bodies.
The RAC was described as a technical committee whose
goals were to consider the current state of knowledge and
technology regarding DNA recombinants, their survival in
nature and the potential for transfer of genetic materials to
the organism. It also considered hypothetical hazards and
methods of monitoring and minimizing risk. Approximately
one-third of the 25 members did not have scientific exper-
tise, but represented public interest and attitudes. This
balance was intended to provide a forum for open public
debate of social and scientific issues associated with recom-
binant DNA research. The RAC is viewed as being over-
whelmingly successful in achieving this goal. Recently,
review of all protocols by the RAC was discontinued after
24 years, but the group maintains its advisory role. These
statements are paraphrased from the Missions Statement of
the Recombinant DNA Advisory Committee (352).
The issues surrounding a waiver of informed consent for
the conduct of research with more than minimal risk bear
similarity to the public concerns with regard to the use of
recombinant DNA materials in human and other research
efforts. First and foremost, such a national voluntary advi-
sory body dealing with research to be conducted with a
waiver of informed consent could provide quality control on
the research itself. The advisory body would be composed of
a significant number of scientific and physician experts in
the areas of emergency cardiac care and would be available
to assess the issue of importance of research to be conducted
with a waiver of informed consent. Does the state of medical
knowledge now allow an acceptance of equipoise between
the proposed arms of the study? Is there a valid possibility
that treatment of this disease will be improved through
inclusion in the intervention arm of the study? Are the risks
considered to be reasonable by broad and nationally re-
spected groups of physicians and scientists? Will the study
design that is proposed have a high probability of success in
demonstrating which of the alternative strategies is more
effective? Are the end points that are proposed measurable
and important? Is the sample size reasonable for assessing
the primary and secondary end points of the proposed
study? Making such judgments could be either advisory to
the local IRBs, the FDA, the NIH, or sponsors.
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Because this proposed national advisory body would have
a substantial group of public and community representa-
tives, as well as scientific and physician leaders, the advisory
committee itself could provide one form of community
review and input with regard to the conduct of the study.
This input, although remote from the specific community in
which the research is to be conducted, would nonetheless
provide a unique form of community information and
response not available with only local information.
Finally, this national advisory body could provide advice
on the methods used by the investigators to inform the local
community and to provide the means for receiving commu-
nity input. The body could also provide reasonable advice on
how the local IRB and investigators should respond to
objections or concerns expressed by the community or
individuals within the community. The specific details of
information provided to the community, a detailed listing of
expressions of concern or support by the community and the
reasonableness of the response would be disclosed to the
advisory committee. A very difficult problem would be the
serious objection to the conduct of the study by a very small
group of individuals within a broader, well-informed com-
munity wishing to participate. A national advisory body
could provide standards and reasonableness with regard to
denying the objections made by a small number of individ-
uals within a large community. A mandatory national
advisory group review was not recommended, because it was
viewed that this additional step would become another
major delay in the conduct of straightforward research under
a waiver.
CONCLUSIONS
1. The treatment of cardiac arrest is in desperate need of
clinical research on how to improve survival and decrease
disability outcomes.
2. The results of enormous efforts to salvage patients from
cardiac arrest have been extremely disappointing. These
patients are not likely to improve, unless there are
fundamental and applied research efforts to produce
major advances.
3. A critically important target for resuscitation research is
avoidance of severe neurologic disability.
4. Patients in cardiac arrest are unable to provide informed
consent. Their disease has deprived them of autonomy.
Thus, a strong and thoughtful IRB is critical in assessing
the need for and, ultimately, where appropriate, in
granting a waiver of informed consent. Advance direc-
tives should always be honored.
5. As used in the FDA’s regulations on waiver of informed
consent, “prospect of direct benefit to the subject” should
be taken to mean: 1) the therapy is directed to the
patient’s condition that required the waiver; 2) there is at
least as good a chance of a beneficial result as a
deleterious outcome from the intervention; 3) in ran-
domized trials, there is clinical equipoise; and 4) in
nonrandomized trials, the risks and benefits profile of the
experimental treatment is at least as favorable as the
current standard of care.
6. There is a need for a major educational effort to inform
the public and the mass media of these issues, focusing
on the importance of waivers of informed consent.
7. The IRBs and investigators should be provided with
additional education and support toward implementa-
tion of the regulations on waiver of informed consent.
The ACC, American Heart Association (AHA), Society
for Academic Emergency Medicine (SAEM), American
College of Emergency Physicians (ACEP), American
Academy of Neurology (AAN), American Society of
Anesthesiology (ASA), National Association of Emer-
gency Medical Services Physicians (NAEMSP) and
other professional societies should have a leadership role.
The final rule advanced by the FDA in 1996 provides
researchers with an opportunity to do resuscitation stud-
ies in circumstances in which individual patients are
unable to provide prospective informed consent. The
final rule clearly states the criteria for applying the waiver
of informed consent, but gives limited guidance for its
implementation. The number of resuscitation studies for
which waiver of informed consent apply is limited, and
IRBs and principal investigators may not be familiar or
have experience with the regulations providing for waiver
of informed consent. A substantial number of questions
concerning its implementation have arisen. In addition,
to date, there has been limited experience with the new
regulations, and no prototype for its implementation
exists. Although the FDA promises a guidance state-
ment giving suggestions for implementing the regula-
tions, this statement is still in the process of final
approval. Even after it is approved, it is likely that IRBs
and investigators will need education and support to
implement the regulations. Therefore, we believe that
professional organizations such as the ACC, AHA,
SAEM, ACEP, AAN, ASA and NAEMSP should
develop strategies to educate and support researchers and
IRBs in implementing the regulations regarding waiver
of informed consent. One strategy might be for each
organization to identify experts within its own member-
ship who are familiar with the regulations, understand
their purpose and spirit and have some knowledge of
existing methods of implementing them. In addition,
these organizations should advertise the availability of
consultants within the organization who can assist in-
vestigators in determining the best methods of imple-
menting the regulations on a protocol-by-protocol basis.
These organizations should also make the availability of
this expertise known beyond their membership, so that
investigators with no official means of receiving such
counsel might have the ability to discuss projects and
implementation strategies with knowledgeable individu-
als representing the resuscitation research community as
a whole. Organizations should develop didactic pro-
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grams regarding implementing the waiver for presenta-
tion at national meetings and have literature available for
researchers. The support and education regarding imple-
mentation of the regulations given by these various
professional organizations may require some financial
assistance of the organizations. This commitment is an
important mission of these professional organizations,
whose members include resuscitation researchers com-
mitted to advancing the emergency care of their patients
and society.
The ACC should, as a consequence of this 31st
Bethesda Conference, be positioned to rapidly provide
input to the anticipated FDA-drafted guidance docu-
ment on implementation of the regulation on waiver of
informed consent.
The 1996 FDA regulations provide for waiver of
informed consent in life-threatening emergencies. Un-
fortunately, there is a widespread misunderstanding
among sponsors, clinical investigators and IRBs of some
of the provisions of the regulations, particularly with
respect to the degree to which participation in the study
must provide a positive benefit to each individual subject
and in the areas of community consultation and public
notification. A draft guidance document that addresses
all aspects of the informed consent waiver process is in
final preparation at FDA. The ACC should actively
participate in public comment on the draft guidelines.
8. An official advisory group should serve as an optional
resource to local IRBs, the FDA, sponsors and individual
or groups of investigators, and may be called on for
advice by any of these sources. This group should be
constituted under the auspices of a concerned federal
government body.
Many IRBs are reported to be unfamiliar with or
uncertain as to how to practicably apply the waiver of
informed consent regulation. In addition, FDA staff,
sponsors or groups of investigators may have internal
disagreements on how to discharge their responsibilities
with regard to a proposed investigation. The conferees
believe that for these groups, and where a protocol will
involve multiple centers and hence multiple IRBs, it
would be valuable to have an authoritative independent
national forum. This optional forum would provide
broadly applicable evaluation and advice on how to meet
the requirements of the waiver regulation before consid-
eration of a given protocol on an institution-by-
institution basis. Therefore, the conferees recommend
that the federal government make available an advisory
committee to provide review, on a request basis, of
clinical investigations that plan to use the waiver of
informed consent provisions. This committee, modeled
after RAC, might be either an independent advisory
committee for these specific issues or a panel constituted
under the charter of an existing committee with appro-
priate jurisdiction (e.g., an FDA advisory committee
supplemented with patient or public representatives and
specialists in bioethics and communication). The advi-
sory committee should, in conjunction with its secretar-
iat, have the discretion to accept for review and discus-
sion those topics which give rise to significant new issues
and decline any issues believed to be settled by previous
similar experience or better handled at the local IRB
level. The scope of the advice offered should include the
full range of likely controversial topics raised by the
waiver regulations or available guidance on implementa-
tion of them. This would include the ethics of informed
consent waiver in a given protocol, the scientific support
for the proposed study, whether there is clinical equi-
poise regarding the treatments, trial design issues, the
appropriateness and adequacy of the proposed mecha-
nism for public input and informing the public of the
trial.
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